




























Constitutive photomorphogenic 1 (COP1) is a ubiquitin E3 ligase that has been implicated in 
development of a variety cancers. The goal was to characterise the ubiquitin E3 ligase 
activity of COP1 and the relationship between COP1 and its interaction partners—especially 
the substrate adapters, TRIB1 and TRIB2 in order to better understand their role in 
tumourigenesis.  
 
COP1 consists of a N-terminal RING domain and a C-terminal seven bladed β-propeller fold 
(WD40 domain), connected by a central coiled-coil. As well as direct substrates, the COP1 
WD40 domain binds to the C-terminal tails of TRIB1/2, which recruit further substrates 
through their pseudo-kinase domains. An expression system for the COP1 WD40 domain in 
insect cell lines from Spodoptera frugiperda and Trichoplusia ni was developed. The ternary 
interactions between COP1, TRIB1, and their substrate C/EBPα were characterised using 
fluorescence polarisation assays. The evidence presented indicates that the interaction of 
C/EBPα with TRIB1 induces conformational change in TRIB1, which releases the TRIB1 
C-terminal tail for interaction with COP1. The relationship between oligomerisation of the 
COP1 and its ubiquitin E3 ligase activity, was investigated using multiple-angle light 
scattering and in vitro activity assays. These analyses have revealed that the oligomerisation 
of COP1 is crucial for its ubiquitin E3 ligase activity. Specifically, dimerisation mediated by 
the coiled-coil domain significantly enhances the ubiquitin E3 ligase activity of COP1—a 
common feature of RING-type ubiquitin E3 ligases. Together, these experiments will help 
elucidate the mechanism through which COP1 functions as a ubiquitin E3 ligase and the 
interaction with substrates recruited by TRIB1/2, which will guide our understanding of 
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Chapter 1 – Introduction 
1.1 Foreword 
The role and functional mechanisms of constitutive photomorphogenic 1 (COP1) in 
mammals are multifaceted. Originally identified in plants, the majority of the knowledge of 
this protein is derived from the study of COP1 in the context of plant biology. Due to this, the 
introduction to this study will begin with the historical evidence that built the basis for 
understanding the function and role of COP1 in plants. Following this, the introduction will 
delve into the continuing characterisation of COP1 in mammalian systems.        
1.2 COP1 identified in Arabidopsis thaliana 
Arabidopsis thaliana (A. thaliana) and other higher plants can develop in two separate ways, 
depending on light conditions. These different development pathways are known as 
photomorphogenesis; the light-induced development pathway, and skotomorphogenesis; the 
development pathway induced in the absence of light (McNellis and Deng, 1995). Whilst 
investigating the mechanism of how light signals are transduced to affect the expression of 
genes involved in these developmental pathways, a genetic locus was discovered that 
appeared to play a pivotal role in the signal transduction process (Deng et al., 1991). A. 
thaliana seedlings that carry mutations in this locus, are morphologically similar when grown 
in the dark to wild-type seedlings grown in the light, therefore the mutant seedlings are 
considered constitutively photomorphogenic. Thus, the locus was named cop1 (constitutively 
photomorphogenic). Further genetic investigation led to the conclusion that the product of the 
wild-type cop1 locus (COP1), is an important switch component in the signal transduction of 
light as a developmental stimulus, and that its role is as a repressor of photomorphogenic 
development (Deng et al., 1991). Continued investigation of the cop1 locus showed that 
severe mutation of the locus is lethal, supporting its importance in development (Deng and 
Quail, 1992). Following this, sequence analysis of the locus identified COP1 as a novel 
protein that consists of a zinc-binding motif, a coiled-coil domain and WD40 repeats (Deng 
et al., 1992). Further characterisation of the zinc-binding domain revealed that it defined a 
new class of cysteine-rich zinc-binding motif, known as a RING finger motif (von Arnim and 
Deng, 1993). However, how exactly this protein functioned to perform its important role was 
still a mystery.  
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1.3 The role of COP1 in plants: repression of photomorphogenesis 
Following the initial identification of COP1 as a regulatory switch between plant 
development patterns, further investigation began to piece together the surrounding pathway. 
The hypothesis that COP1 acts as a repressor of photomorphogenesis (Deng and Quail, 1992) 
requires a mechanism of COP1 inactivation when photomorphogenesis is the preferred 
development pathway. This mechanism became apparent when the subcellular localisation of 
COP1 was investigated, discovering that nucleocytoplasmic partitioning causes light-induced 
inactivation of COP1 (von Arnim and Deng, 1994). This essentially means that COP1 
performs its repressive role within the nucleus, however stimulation by light induces 
nucleocytoplasmic partitioning, resulting in reduced levels of nuclear COP1 and allowing the 
photomorphogenic pathway to proceed. Before this discovery, it was unclear how COP1 was 
able to regulate gene expression. The knowledge that COP1 is found within the nucleus (von 
Arnim and Deng, 1994) suggested that COP1 might either act directly on DNA by interacting 
with the promoter sequences of target genes, or indirectly by interacting with transcription 
factors. Evidence began to accumulate supporting the latter, foremost of which involved 
interaction studies indicating that COP1 negatively regulates a bZIP transcription factor, and 
that the interaction between COP1 and the transcription factor named HY5 is direct and 
specific (Ang et al., 1998). HY5 is a light-induced positive regulator of photomorphogenesis 
(Chattopadhyay et al., 1998), demonstrating that COP1 interacts with and regulates other 
proteins directly, especially transcription factors—rather than acting on DNA itself. As 
shown, the pathway through which COP1 acts to repress photomorphogenesis was becoming 
clearer. However, at this point there was still no precise evidence of how COP1 functionally 
repressed its supposed interaction partners.         
1.4 COP1: a plant ubiquitin E3 ligase  
The mechanism by which COP1 exercised repression on light-induced transcription factors 
was alluded to by several important pieces of evidence. Firstly, the modification of proteins 
with chains of ubiquitin (a process known as ubiquitylation) was being recognised as a highly 
conserved system of post-translational modification, that resulted in biological outcomes such 
as targeting for proteasomal degradation (Hershko and Ciechanover, 1998). This is important 
because whilst attempting to identify novel ubiquitin E3 ligases (a key enzyme in the process 
of ubiquitylation) it was determined that RING finger motifs can possess the ability to 
perform E2-dependent ubiquitylation (Lorick et al., 1999). As previously detailed, COP1 
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possesses a RING finger motif, and was soon shown to be associated with the targeted 
proteasomal degradation of HY5. This led to the postulation that COP1 might either by itself, 
or in association with other proteins act as a ubiquitin E3 ligase, specifically targeting HY5, 
and likely multiple other substrates for proteasomal degradation (Osterlund et al., 2000). 
However, it was later observed that COP1 Interacting Protein 8 (CIP8), which also contains a 
RING finger motif, is the essential protein for the ubiquitylation of HY5. Additionally, an 
observed interaction between COP1 and CIP8 suggested a complex that mediates the 
proteasomal degradation of HY5 (Hardtke et al., 2002). This however, does not mean that 
COP1 is definitely void of ubiquitin E3 ligase activity. COP1 was soon shown to perform 
auto-ubiquitylation, as well as the direct ubiquitylation of another light responsive 
transcription factor LAF1 (Seo et al., 2003). This shows that in A. thaliana COP1 appears to 
have multiple mechanisms of promoting ubiquitylation of a substrate, either directly as with 
LAF1, or indirectly via associated proteins as with HY5 (Figure 1.1). Through these 
mechanisms COP1 performs its regulatory role in development by promoting the ubiquitin-
mediated proteasomal degradation of light responsive transcription factors, thus repressing 
photomorphogenic development when necessary (Hoecker, 2005).  
Figure 1.1. Schematic of the function of COP1 in plants. Light can inhibit the function of COP1 by 
inducing nucleocytoplasmic partitioning, essentially excluding COP1 from the nucleus where it 
performs its role. When in the nucleus (light grey) COP1 functions as a ubiquitin E3 ligase, 
poly-ubiquitylating substrates and targeting them for proteasomal degradation. This can occur 
through the intrinsic ubiquitin E3 ligase activity of COP1 (LAF1) or through associated proteins 
(HY5). By targeting light-induced transcription factors for degradation via the mechanism shown, 
COP1 represses photomorphogenesis.      
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1.5 COP1: a mammalian ubiquitin E3 ligase  
Thorough screens of protein sequence databases identified a mammalian homologue of COP1 
(Wang et al., 1999). A human and a mouse homologue were first discovered, which shared 
reasonable sequence homology—especially in the RING and WD40 repeat domains 
(Figure 1.2). Wang et al. (1999) also showed that a chimeric human/mouse COP1 construct 
was subject to nucleocytoplasmic partitioning in transgenic plants, suggesting that the 
mammalian COP1 (mCOP1) might perform a similar regulatory role to its homologue in 
plants. Characterisation of the mCOP1 revealed that it is also associated with ubiquitylated 
proteins, and is itself ubiquitylated—suggesting that, equivalent to its plant homologue 
mCOP1 is a RING ubiquitin E3 ligase (Yi et al., 2002). 
 
Including RING-type, there are three families of ubiquitin E3 ligase characterised by their 
catalytic mechanism. HECT and RBR-type ubiquitin E3 ligases are similarly characterised by 
forming a thioester intermediate with the donor ubiquitin, but differ in their use of structural 
components to facilitate the ubiquitin transfer process (Morreale and Walden, 2016). RING 
ubiquitin E3 ligases such as COP1, do not form a catalytic intermediate with ubiquitin in the 
transfer process, instead they provide a scaffold which facilitates the transfer of the ubiquitin 
from the E2~ubiquitin conjugate to the target substrate—without catalysing the reaction 
directly.  
1.6 The elusive role of COP1 in mammals 
Once the mCOP1 homologue had been validated, research began to investigate possible roles 
of this protein within mammalian systems. Specifically, investigation of mCOP1 interaction 
partners, and whether its association with the ubiquitin system indicates ubiquitin E3 ligase 
activity. However, the role of COP1 in mammals is still not entirely understood. This is likely 
Figure 1.2. Alignment of the predicted secondary structures of the plant and mammalian COP1. Despite the longer 
length of the mammalian homologue (mCOP1) compared to the A. thaliana COP1 (AtCOP1) the three key 
domains of COP1 are reasonably conserved. Adapted from Wang et al. (1999).  
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due to COP1 playing a part in various biological pathways, inferred by studies performed on 
COP1 deficient mice. The deficient mice exhibit dysregulation in differentiation, cell 
proliferation, cell fate and survival pathways (Marine, 2012). Supporting this is the wide 
range of identified interaction partners including proteins such as c-Jun, p53, acetyl-CoA 
carboxylase (ACC), FOXO1, TORC2, and ETS1 (Dornan et al., 2004; Wertz et al., 2004; Qi 
et al., 2006; Dentin et al., 2007; Kato et al., 2008; Lu et al., 2014). The range of interaction 
partners show that COP1 is associated with a variety of functions such as lipid metabolism, 
gluconeogenesis, and tumourigenesis. 
1.7 The link between COP1 and cancer  
As mentioned above, the role of COP1 in mammals is elusive and to complement this, the 
role of COP1 in cancer also seems ambiguous. COP1, along with all other ubiquitin E3 
ligases, is important for determining the specificity of protein substrates for ubiquitylation, as 
well as the type of ubiquitin chain attached to a substrate. Due to this important role, the 
human genome encodes hundreds of ubiquitin E3 ligases (Marine, 2012). There is 
compelling evidence of an association between ubiquitin E3 ligases and cancer. This is likely 
because mutations in a ubiquitin E3 ligase may lead to, increased targeting of tumour 
suppressive factors, or decreased targeting of oncoproteins for degradation. However, the 
effect of mutations in a ubiquitin E3 ligase can be ambiguous, because most ubiquitin E3 
ligases target multiple substrates that may have opposing effects. For example, some may 
inhibit tumorigenesis, whilst others promote it (Marine, 2012). This appears to be the case for 
COP1, as it has been implicated as both an oncoprotein and a tumour suppressive factor.  
 
The role of COP1 in regulating the tumour-suppressor protein p53, indicated COP1 as an 
oncoprotein. Loss of p53 is frequently associated with cancer, due to its role in inducing 
apoptosis, senescence, and cell cycle arrest in response to a variety of cellular stresses. 
Greater than 50% of all human tumours possess a p53 mutation (Vousden and Lu, 2002). Due 
to the clear risk of the dysfunction of p53, its protein levels are tightly regulated through 
interaction with a number of ubiquitin E3 ligases, including COP1 (Wang et al., 2010). For 
example, COP1 is expressed at abnormally high levels in some hepatocellular carcinomas 
resulting in loss of p53 function (Lee et al., 2010). Additionally, COP1 induces the 
proliferation of human glioma cells by down-regulating p53 (Zou et al., 2016). Therefore, the 
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up-regulation of COP1 in a number of human cancers suggests that, in certain contexts COP1 
promotes cancerous processes via dysregulating p53 (Dornan et al., 2004).  
 
Conversely, COP1 regulates the proto-oncogenic transcription factor c-Jun, which is involved 
in regulating many cellular processes and can induce oncogenic transformation. 
Dysregulation of c-Jun has been implicated in various of cancer types (Karin, 1995; Shaulian 
and Karin, 2002; Weiss and Bohmann, 2004). Additionally, COP1 deletion is observed in 
various cancers, and COP1 deficient mice develop tumours at an accelerated rate (Migliorini 
et al., 2011). Therefore, regulation of known oncoproteins c-Jun and ETS1, suggests a 
tumour suppressive role for COP1 (Bianchi et al., 2003; Lu et al., 2014).          
1.8 Multiple mechanisms of ubiquitin E3 ligase activity 
It has been mentioned that mCOP1 makes many interactions, but how is it capable of 
performing its role on varied substrates? As in A. thaliana, mCOP1 has been shown to 
promote substrate ubiquitylation through multiple mechanisms. The different mechanisms 
through which COP1 can promote substrate ubiquitylation can be classified into three main 
categories (Figure 1.3).    
Figure 1.3. Schematic of the multiple 
mechanisms through which COP1 can 
promote substrate ubiquitylation. COP1 
can promote substrate ubiquitylation via 
direct substrate recruitment and intrinsic 
activity (A). COP1 can promote 
substrate ubiquitylation via indirect 
substrate recruitment and intrinsic 
activity (B). COP1 can promote 
substrate ubiquitylation via direct 
substrate recruitment and extrinsic 






Firstly, COP1 can promote ubiquitin transfer to a target substrate via direct substrate 
recruitment and intrinsic ubiquitin E3 ligase activity (Figure 1.3a). An example of this is the 
tumour-suppressor protein p53. COP1 directly interacts with p53 (Moscetti et al., 2018) and 
regulates its stability via ubiquitylation (Dornan et al., 2004; Wang et al., 2010).  
 
Secondly, COP1 can promote ubiquitin transfer to a target through intrinsic ubiquitin E3 
ligase activity, but indirect substrate recruitment—such as through a substrate adapter 
(Figure 1.3b). An example of this is the regulation of CCAAT-enhancer binding protein α 
(C/EBPα) stability by COP1, through the associated pseudo-kinase and substrate adapter 
TRIB1 (Section 1.9).  
 
Thirdly, COP1 has been demonstrated to promote ubiquitylation by directly recruiting 
substrates and using the activity of a separate ubiquitin E3 ligase (Figure 1.3c). For example, 
the oncoprotein c-Jun is tightly regulated by a large ubiquitin E3 ligase complex composed of 
multiple regulatory and structural protein subunits including; DDB1, DET1, CUL4, 
RING-box protein 1 (RBX1) and COP1 (CUL4 complex) (Wertz et al., 2004). In the context 
of regulating c-Jun stability COP1 acts as the substrate adaptor, interacting directly with 
c-Jun, whilst the ubiquitin E3 ligase activity is provided by the RBX1 component. Therefore, 
COP1 can promote the ubiquitylation of a substrate via direct substrate recruitment but using 
the activity of another ubiquitin E3 ligase.  
1.9 COP1, TRIB1 and C/EBPα 
The CCAAT-enhancer binding protein family (including C/EBPα) are a group of human 
transcription factors that are involved in a variety of cellular processes including the 
metabolism, differentiation, and proliferation of cells—especially adipocytes, hepatocytes 
and hematopoietic cells (Ramji and Foka, 2002; Di Stefano et al., 2013; Ye et al., 2013). 
C/EBPα specifically, is an important transcription factor in myeloid differentiation and has 
been shown to be associated with leukemogenesis. For example, as much as 10% of acute 
myeloid leukemia (AML) patients possess C/EBPα mutations (Nerlov, 2004; Koschmieder et 
al., 2009). Genetic modification of the mouse C/EBPα locus revealed that this protein is a 
crucial tumour suppressor in hematopoietic lineages, as a knockout mutation resulted in fully 
penetrant AML (Kirstetter et al., 2008). The regulation of C/EBPα became elucidated by four 
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critical pieces of evidence. Firstly, it was noticed that the mammalian homologues of the 
highly conserved Tribbles protein (TRIB1, TRIB2 and TRIB3) each contain a COP1-binding 
motif (Qi et al., 2006). This was linked to the second piece of evidence that showed that 
TRIB1 and TRIB2 promote the degradation of C/EBPα (Dedhia et al., 2010). Subsequently, 
it was shown that COP1 and TRIB1 or TRIB2 form a complex that regulates C/EBPα 
stability through the intrinsic ubiquitin E3 ligase activity of COP1 (Yoshida et al., 2013), and 
importantly that either TRIB1 or TRIB2 is required as a substrate adaptor in complex with 
COP1 for the promotion of C/EBPα degradation (Keeshan et al., 2010). This is important as 
it indicated a previously undocumented mechanism through which mCOP1 promotes 
substrate ubiquitylation, as detailed in section 1.8. 
 
The association between COP1, TRIB1 and C/EBPα prompted the first biophysical 
interaction studies involving COP1. Initially it was revealed that the COP1-binding motif of 
TRIB1, located near the C-terminus, is secured by its own N-lobe in what is suggested to be a 
form of auto-inhibition (Murphy et al., 2015). Structural studies by Uljon et al. (2016), 
provided crystal structures of the COP1 WD40 domain in complex with a C-terminal peptide 
of TRIB1, indicating the WD40 domain was necessary and sufficient for binding TRIB1 
(Figure 1.4). This delivered insight into the nature of the interaction between COP1 and 
TRIB1. Conclusions drawn from this included that the WD40 domain of COP1 binds the 
TRIB1 COP1-binding motif on the top face of its seven-bladed β-propeller structure, 
supporting the hypothesis that TRIB1 is a substrate adaptor and not a substrate itself—also 
that this interaction is shared and competed for by other COP1 substrates.    
Figure 1.4. Structures of the TRIB1 C-terminal tail bound to the COP1 WD40 domain or TRIB1 N-lobe. Structural data 
(PDB: 5IGQ) of the TRIB1 C-terminal tail (orange) bound to the top face of the COP1 WD40 domain (blue) 
form Uljon et al. (2016), is shown from two different angles (A). Structural data (PDB: 5CEM) of the TRIB1 
C-terminal tail (orange) bound to the N-lobe of TRIB1 (grey) from Murphy et al. (2015) (B).        
B A 
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1.10 Investigating mammalian COP1 
This study focused on expanding the current understanding of mCOP1. As discussed in 
section 1.9, recent data has provided a step forward in understanding the nature of the 
mechanisms through which mCOP1 interacts with both substrates, and substrate adaptors to 
promote ubiquitylation. However, there are still missing pieces to the puzzle. Investigation 
into the ubiquitin E3 ligase activity and interactions of COP1, will help to clarify the 
mechanisms that allow it to operate in a variety of biological pathways, on an array of 
substrates. This in turn may help explain the elusive role of COP1 in cancer. 
 
Specifically, this study focused on investigating the hypothesis that the ubiquitin E3 ligase 
activity of COP1 is related to its oligomeric state, and that this relationship is mediated 
through the coiled-coil domain. This hypothesis was tested using in vitro biochemical 
analysis of COP1 ubiquitin E3 ligase activity. Additionally, this study investigated the 
hypothesis that binding of C/EBPα to TRIB1 results in conformational changes in TRIB1, 
that facilitate the binding of COP1 to the TRIB1 C-terminal tail. This hypothesis was tested 
using fluorescence polarisation based binding studies.  
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Chapter 2 – Materials and Methods 
2.1 General methods 
Unless stated otherwise, all solution and media were prepared using sterile type 1 ultrapure 
water (18.2 MΩ) from a Milli-Q A10 academic water purification device (Millipore). All 
buffers for size exclusion and ion exchange chromatography were vacuum-filtered using a 
0.45 µm pore filter and degassed for a minimum of 20 minutes. All chemical reagents utilised 
in this study were purchased from either AppliChem, BioFroxx, Merck, or ScharLab, unless 
mentioned otherwise. All chemical reagents were of analytical grade. All centrifugation steps 
used either an Allegra™ X-30 R (Beckerman Coulter) centrifuge, an Avanti™ JXN-26 
(Beckerman Coulter) centrifuge, an Eppendorf 5417R (Eppendorf) micro-centrifuge, or a 
Biofuge Pico (Heraeus Instruments) micro-centrifuge.  
2.2 General cloning methods  
All primers used in this study were purchased from either Sigma, or Integrated DNA 
Technologies (IDT). Primers were suspended in Ultrapure water (Invitrogen) to a final 
concentration of 100 pmol.mL-1 and stored at –20 °C. Unless stated otherwise, all cloning 
reagents were purchased from New England Biolabs. A list of all the primers utilised in this 
study, is available in Appendix A. All cloning reactions were performed using a C1000 
thermal-cycler™ (Bio-Rad), for which a list of the PCR protocols used is available in 
Appendix B. Approximate quantification of DNA was performed via measuring absorbance 
at 260 nm (A260) using a Nanodrop™ ND-1000 spectrophotometer (Thermofisher). All 
constructs generated in this study were sequence confirmed via Sanger sequencing at either 
the Otago Genetics Analysis Service, or Massey Genome Service.  
2.2.1 Agarose gel electrophoresis 
Tris-Acetic acid-EDTA (TAE) agarose gels were used to resolve DNA products of cloning 
procedures. The TAE buffer used for electrophoresis was composed of 40 mM Tris-HCl at 
pH 8.0, 20 mM acetic acid and 1 mM EDTA. The agarose gel itself was made by dissolving 
0.5%–1.5% (w/v) HyAgarose™ (HydraGene) in TAE buffer. DNA samples were mixed with 
Gel Loading Dye Purple 6 × (New England Biolabs) prior to loading. Electrophoresis was 
run at 120 volts (V), 135 milliamps (mA) for 25 minutes. Gels were stained using ethidium 
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bromide (approximately 0.5 µg.mL-1) to facilitate visualisation under UV-light. The relative 
size of DNA bands was estimated via comparison to Quick-Load® 2-Log DNA ladder (New 
England Biolabs).                
2.2.2 Generation of COP1 expression vectors  
An expression vector of Homo sapiens COP1 (residues 110–731) was already available in the 
Mace laboratory. From this original COP1 construct, the cDNA of selected COP1 constructs 
of interest were generated via PCR amplification. Appropriate primers were designed to 
amplify the DNA of interest, including complementary ligation independent cloning (LIC) 
overhangs for subsequent cloning (Berrow et al., 2007). The PCR amplification of COP1 
constructs was performed in 25 µL reactions; containing approximately 20 to 50 ng of 
template DNA, 20% (v/v) 5 × buffer with Mg2+, 700 µM deoxynucleotide triphosphates 
(dNTPs), 25 pmol of both forward and reverse primers, and 0.5 U of Q5® High-Fidelity 
DNA polymerase. The PCR reactions were performed using a thermal-cycler and protocol 
Q5 (Appendix B), and analysed via TAE agarose gel electrophoresis (Section 2.2.1). DNA 
products of expected sizes were extracted from the gel using a Zymoclean™ gel DNA 
recovery kit (Zymo Research) as per the manufacturer’s instructions. Purified DNA was 
quantified using A260 and then used in a ligation independent cloning reaction (Section 2.2.3). 
A schematic of all the COP1 constructs generated in this study can be found in Appendix C. 
2.2.3 Ligation Independent Cloning  
LIC was performed as detailed by Berrow et al. (2007). The vector was digested and 
linearised with KpnI. Vector linearisation involved incubating approximately 1 µg of vector 
DNA with 10 U of KpnI-HF and 20% (v/v) Cutsmart buffer at 37 °C for 2 hours, followed by 
resolution of the reaction product by TAE agarose gel electrophoresis (Section 2.2.1). The 
vector DNA successfully linearised by KpnI was extracted from the gel using a Zymoclean™ 
gel DNA recovery kit (Zymo Research) as per the manufacturer’s instructions. Subsequent 
T4 polymerase treatment was performed with approximately 800 ng of KpnI linearised 
vector, 4 U of T4 DNA polymerase, 10% (v/v) NEB buffer 2 and 250 µM dTTP and 
incubated using a thermal-cycler set and protocol LIC (Appendix B).  
 
T4 polymerase treatment of the insert was performed with approximately 100 ng of insert 
DNA (Section 2.2.2), 5 U.mL-1 of T4 DNA polymerase per 100 ng of DNA, 10% (v/v) NEB 
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buffer 2 and 250 µM dATP and incubated using a thermal-cycler and protocol LIC 
(Appendix B). Following these two reactions, the insert and vector were mixed together in a 
2 µL reaction (0.5 µL vector and 1.5 µL insert) and incubated at room temperature for 5 
minutes. This final reaction was used in a transformation into competent Escherichia coli (E. 
coli) cells. 
2.2.4 Site-directed mutagenesis  
Point mutations were introduced via a method of site-directed mutagenesis known as 
QuickChange mutagenesis (Stratagene) developed by Liu and Naismith (2008). 
QuickChange mutagenesis was performed using approximately 20 ng of plasmid containing 
the wild type (WT) insert, 20% (v/v) 5 × buffer with Mg2+, 200 µM dNTPs, 5 pmol of 
forward and reverse primers and 20 U.mL-1 of Q5®High-Fidelity DNA polymerase, 
incubated in a thermal-cycler using protocol QC (Appendix B). The resulting PCR reaction 
was treated with DpnI, in order to remove the template DNA. The DpnI mixture was 
incubated at 37 °C for 4 hours. The mixture was then used for transformation of competent E. 
coli cells via the method described (Section 2.3.4). 
2.3 Bacterial expression systems   
2.3.1 Vectors for recombinant protein expression in bacterial cell culture 
The proteins used in this study were generated as fusion proteins to allow for simple 
purification methods. The main vector used in this study was a modified pET-28 plasmid 
including a N-terminal hexa-histadine (His6) tag, a ligation independent cloning (LIC) site, 
and a Human Rhinovirus 3C (HRV 3C) protease cleavage site between the His6 tag and the 
protein of interest. A modified pMAL plasmid with a N-terminal His6-Maltose Binding 
Protein (MBP) tag, a LIC site and HRV 3C protease cleavage site between the MBP and 
His6, was also used as an alternative vector. These tags allowed for straightforward 
purification of the fusion protein from cell lysate via the specific interaction between the His6 
and Ni2+ (immobilised metal-ion affinity chromatography; IMAC). The HRV 3C protease 
cleavage sites facilitated the removal of the tag(s) from the fusion proteins if desired. The 
pET-28 and pMAL plasmids both included antibiotic resistance cassettes, conferring 
resistance to kanamycin and ampicillin respectively. These antibiotic resistance cassettes 
allowed for selection of successfully transformed bacteria in a selective growth environment.         
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2.3.2 Escherichia coli strains 
The Escherichia coli (E. coli) strain BL21 (DE3) was used for expression of protein 
constructs. For all general cloning procedures, the E. coli the strain MC1061 was used. 
2.3.3 Bacterial cell culture 
Liquid Media: Growth of E. coli cultures for either protein expression or cloning was 
performed in Lysogeny Broth (LB). LB consists of 10 g.L-1 casein pancreatic peptone 
(tryptone), 10 g.L-1 NaCl and 5 g.L-1 yeast extract. Once prepared the medium was sterilised 
via autoclaving at 121 °C, 15 psi for 20 minutes. Prior to use, medium was supplemented 
with either kanamycin (50 µg.mL-1) or ampicillin (100 µg.mL-1), depending on the 
recombinant plasmid in use.  
 
Solid Media: Transformed E. coli colonies were grown on solid agar plates. These agar plates 
were prepared via addition of 1.5% (w/v) agar to LB prior to sterilisation. Following 
sterilisation the relevant antibiotic was added to the LB-agar at equivalent concentrations to 
the liquid media. Plates were poured using aseptic technique in order to maintain sterility, 
and then were allowed to set before being stored at 4 °C. 
2.3.4 Transformation of competent cells 
The E. coli MC1061 cells were made chemically competent (Hanahan et al., 1991). 
Transformation of MC1061 cells was performed via the addition of 2 µL of the LIC vector 
and insert reaction (Section 2.2.3) to 50 µL of competent MC1061 cells. This mixture was 
incubated on ice for 10 minutes before being heat shocked at 42 °C for 45 seconds. 
Immediately after this heat shock, the cells were returned to ice to incubate for a further 2 
minutes. Subsequently, the cells were supplemented with 350 µL of sterile LB and incubated 
for 45 minutes in a Innova 4300 incubator (New Brunswick) at 37 °C, and a constant 215 
rpm. Using aseptic technique, the entire mixture was spread onto an agar plate containing the 
corresponding antibiotic for the recombinant plasmid. This agar plate was incubated 
overnight (O/N) at 37 °C. Following O/N incubation the agar plate was inspected and 
promising colonies were selected for colony PCR.  
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2.3.4.1 Colony PCR  
Colony PCR involved the preparation of a separate PCR reaction for each colony from the 
agar plate that was to be examined. These reactions were performed in 25 µL reactions 
containing 10% (v/v) ThermoPol® reaction buffer, 700 µM dNTPs, 10 pM of forward and 
reverse primers (Appendix A) and 25 U.mL-1 of Taq DNA polymerase. A small sample of the 
colonies of interest was transferred into their respective PCR reactions, which were then 
performed using a thermal-cycler and protocol Colony (Appendix B). The resulting PCR 
reactions were analysed via TAE agarose gel electrophoresis (Section 2.2.1). Colonies 
identified by Colony PCR to contain the expected insert were used to inoculate 3 mL of 
sterile LB. Before inoculation, the relevant antibiotic was added at the concentrations 
previously mentioned (Section 2.3.3). Once inoculated, the 3 mL culture was incubated O/N 
at 37 °C, 215 rpm. 
2.3.4.2 Purification of recombinant vector  
The culture grown O/N was used in a plasmid extraction using a Zyppy™ plasmid miniprep 
kit (Zymo Research) as per the manufacturer’s instructions. The plasmid DNA recovered 
from this process was quantified using A260 and then stored until required at –20 °C. The 
validity of the insert was confirmed via sequencing analysis. 
2.4 Insect expression systems 
The system for protein expression in insect cell culture utilised in this study is known as the 
Bac-to-Bac baculovirus Expression System (Thermofisher). The Bac-to-Bac system uses 
recombinant baculovirus (Ciccarone et al., 1998) as a vector for the high-level expression of 
a protein of interest in insect cell culture—based on the research of Luckow et al. (1993). A 
schematic of the overall process of the Bac-to-Bac system is shown in Figure 2.1.  
2.4.1 Vectors for recombinant protein expression in insect cell culture 
The first vector of this system is the pFastBac™ vector, into which the constructs of interest 
were initially cloned. The expression cassette of pFastBac™ is flanked by the left and right 
arms of Tn7 transposon. The expression cassette itself contains, a gentamicin resistance gene 
for selection, a SV40 polyadenylation signal which facilitates the formation of a mini Tn7, a 
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polyhedrin promoter (PPH) from Autographa californica multiple nuclear polyhedrosis virus,  
Figure 2.1. Schematic of the overall process of the Bac-to-Bac baculovirus expression system. The gene of interest (blue) 
is cloned into the pFastBacTM plasmid, downstream of a polyhedrin promoter (PPH), and flanked by the arms of a 
Tn7 transposon (Tn7R and Tn7L). Transformation into competent cells followed by selection and DNA purification 
results in the recombinant bacmid. Finally, the recombinant bacmid is used to transfect host insect cells. Host 
insect cell machinery generates the recombinant baculovirus particles used for quantification of the viral titre or 
recombinant gene expression.      
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which confers high expression levels in insect cell culture. This study used a modified 
version of pFastBac™, that contained a LIC cassette for cloning, a N-terminal His6 tag and a 
HRV 3C protease cleavage site between the His6 tag and the protein of interest.  
 
The second major vector of the Bac-to-Bac system is the baculovirus shuttle vector, 
bMON14272 (bacmid). This plasmid is present in the E. coli strain DH10Bac. The bacmid 
features a Kanamycin resistance gene for selection and a DNA segment encoding the LacZα 
peptide, into which the Tn7 attachment site (mini-attTn7) has been inserted. Disruption of the 
LacZα peptide via the insertion of Tn7 inhibits the activity of the β-galactosidase in 
recombinant cells. This disruption forms the basis of Blue/White colony selection that allows 
the identification of DH10Bac containing recombinant bacmid.  
2.4.2 Escherichia coli strain 
The E. coli strain used in the Bac-to-Bac system is the DH10Bac strain. The DH10Bac strain 
hosts a bacmid (Section 2.4.1) and a helper plasmid. The helper plasmid contributes a 
transposase and contains a tetracycline resistance gene. Once DH10Bac cells are transformed 
(Section 2.4.4) with the pFastBac™ vector, transposition of the construct of interest can 
occur between the mini-Tn7 element in the pFastBac™ vector and the mini-attTn7 site on the 
bacmid, resulting in a recombinant bacmid. This recombinant bacmid can then be isolated 
and used to infect insect cells.   
2.4.3 Generation of recombinant pFastBac™ 
Constructs of interest for expression via insect cell culture were generated via the molecular 
biology techniques detailed in 2.2.2. Comparably to bacterial cell culture expression, 
constructs for insect cell culture expression were designed to be LIC compatible, as was the 
pFastBac™ vector. Therefore, the same LIC cloning protocol (Section 2.2.3) was followed 
for generation of recombinant pFastBac™. The validity of the insert in the purified 
recombinant pFastBac™ was confirmed by sequencing analysis.  
2.4.4 Transformation of recombinant pFastBac™ into DH10Bac cells 
Transformation of DH10Bac cells involved preparation of LB agar plates containing 
kanamycin (50 µg.mL-1), gentamicin (7 µg.mL-1) and tetracycline (10 µg.mL-1) in order to 
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provide a selective environment. The plates were spread with 10 µg.mL-1 X-gal in order to 
facilitate the Blue/White selection of recombinant bacmids and 40 µg.mL-1 IPTG to induce 
the expression cassette of the recombinant pFastBac™. The plates were then dried at 37 °C 
prior to inoculation. Transformation was performed via the addition of approximately 1 ng of 
recombinant pFastBac™ into 100 µL of competent DH10Bac cells. The cells were then 
incubated on ice for 30 minutes before being heat shocked at 42 °C for 45 seconds. 
Immediately after heat shock the cells were returned to ice to incubate for a further 2 minutes. 
The cells were supplemented with 900 µL of sterile Super Optimal broth with Catabolite 
repression (S.O.C. medium) and incubated for 4 hours at 37 °C, 215 rpm. Subsequently, a 
three-fold serial dilution was performed on the sample using S.O.C. medium as the diluent, 
and 100 µL of each of the dilutions (× 10-1, × 10-2, and × 10-3) was spread onto one of the 
prepared agar plates. These agar plates were incubated at 37 °C for 48 hours. Following 
incubation, the agar plates were inspected for potentially positive colonies. White colonies 
indicated a successful transformation of recombinant pFastBac™, whilst blue colonies 
indicated a transformation of wild type pFastBac™ (Section 2.4.1). Selected white colonies 
were further verified via colony PCR. Colony PCR was performed as detailed in 2.3.4.1. The 
resulting PCR reactions were analysed via TAE agarose gel electrophoresis (Section 2.2.1). 
Using the information provided by the agarose gel analysis, ‘positive’ colonies from the agar 
plate could be used to inoculate 3 mL of sterile S.O.C. medium, supplemented with the 
previously mentioned concentrations of kanamycin, gentamicin and tetracycline were added 
to the 3 mL of sterile S.O.C. medium. Once inoculated, the 3 mL culture was incubated O/N 
at 37 °C, 215 rpm. 
 
The culture grown O/N was used in a bacmid extraction using a Zymo Research Bac DNA 
miniprep kit (Zymo Research) as per the manufacturer’s instructions. The bacmid DNA 
recovered from this process was quantified using A260 and then stored at –20 °C. 
2.4.5 Insect cell culture 
Three insect cell lines were utilised for the expression of proteins of interest as shown in 




Table 2.1. Insect cell lines used for recombinant protein expression 
Identifier Species Cell line type Company 
SF21 Spodoptera frugiperda Continuous ovarian  Expression Systems 
SF9 Spodoptera frugiperda Continuous ovarian  Expression Systems 
T. ni Trichoplusia ni Continuous ovarian  Expression Systems 
All insect cells were grown primarily in ESF 921 Protein-free insect cell culture medium 
(Expression Systems), Sf-900™ III Serum Free Medium (Life Technologies) was also trialed 
for insect cell culture. All media was stored at 4 °C and was pre-heated to room-temperature 
before cell culture procedures. 
 
All insect cell culture procedures were performed in a HEPA-filtered ventilation laminar flow 
particle exhaust hood. All necessary equipment was sterilised with 70% ethanol prior to use.                
Unless otherwise stated, insect cells were grown at 27 °C and 125 rpm (orbit diameter 
1.9 cm) in a non-humidified, non-CO2 Innova 42 incubator (New Brunswick). 
Continuous cultures of insect cells were grown at a 20 mL culture volume, SF21 and SF9 
continuous cultures were maintained via passaging at alternating 3 and 4 day intervals at 
concentrations of 1 ×	106 and 8 × 105 cells.mL-1 respectively. T. ni continuous cultures were 
maintained via passaging at alternating 3 and 4 day intervals at a concentration of 
5 × 105 cells.mL-1. 
 
Insect cell culture concentrations and percentage cell death were calculated by Trypan Blue 
staining, using a 1:1 mixture of culture and 0.1% Trypan blue solution in a Hemocytometer 
using a light microscope.  
2.4.6 Baculovirus production 
Transfection of insect cell culture with recombinant bacmid DNA was performed with 
FuGENE 6 (Promega). SF21 cells in ESF 921 were plated in a six-well plate, with a 3 mL 
volume at 5 × 105 cell.mL-1 per well, 24 hours prior to transfection. Insect cell medium ESF 
921 and FuGENE 6 were pre-heated to room temperature. Two separate solutions were 
prepared, one consisted of approximately 1 µg of recombinant bacmid DNA and 100 µL of 
ESF 921. The second consisted of 6 µL FuGENE 6 and 100 µL of ESF 921. Subsequently, 
the solutions were combined, gently mixed and then incubated at room-temperature for 30 
minutes. Following incubation, the medium was removed from the adhered cells and the 
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transfection mixture was added to the well dropwise. The six-well plate was gently rocked to 
ensure the transfection mixture covered the entire well and then incubated at room-
temperature for 1 hour, rocking gently every 20 minutes. Subsequently, 3 mL of ESF 921 
was added directly to the well and supplemented with 100 µg.mL-1 of penicillin-streptomycin 
(Life Technologies). The plate was gently rocked and then incubated in a 27 °C incubator 
(without shaking) until 70–80% cell death was observed (late-stage viral infection), 
approximately 3 to 4 days. Once the cells demonstrated signs of late-stage infection, the 
culture was harvested via centrifugation, 500 × g for 5 minutes. The clarified supernatant 
was filtered through a 0.45 µm pore filter and transferred to a sterile 15 mL tube, as the viral 
containing fraction or passage 1 (P1) viral stock. The P1 viral stock was stored until required 
at 4 °C, protected from light.      
 
The P1 viral stock was passaged twice in order to generate a passage 3 (P3) viral stock before 
trial expression experiments were performed. The passaging of the P1 viral stock involved 
the infection of a 20 mL culture of SF21 cells at approximately 1 ×	106 cells.mL-1 (mid-log 
phase) with 1 mL of the viral stock. 	
 
Once infected, the culture was incubated in a 27 °C incubator until 70–80% cell death was 
observed, approximately 3 to 4 days. The culture was harvested via centrifugation at 500 × g 
for 5 minutes. The clarified supernatant was filtered through a 0.45 µm pore filter and 
transferred to a sterile 15 mL tube, as the viral containing fraction or passage 2 (P2) viral 
stock. The P2 viral stock was stored until required at 4 °C, protected from light. This entire 
process was repeated using the P2 viral stock to infect a fresh 50 mL culture, in order to 
produce a working P3 viral stock. The viral titre of the P3 viral stock was calculated via a 
plaque assay as detailed in 2.4.7.      
2.4.7 Plaque Assay for determining viral titre 
A six-well plate was prepared with 3 mL per well of insect cell culture containing 
5 × 105 cells.mL-1. The six-well plate was incubated at room-temperature for 1 hour. The P3 
viral stock to be quantified was vortexed and then a 10-fold serial dilution (× 10-1 to × 10-8) 
was performed using ESF 921 medium as the diluent. The media was carefully removed from 
the adhered cells in the six-well plate, then 100 µL of the dilutions × 10-3, × 10-4, × 10-5, 
× 10-6, × 10-7, and × 10-8 were added to a well. The plate was then incubated at 
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room-temperature for 1 hour, rocking gently every 20 minutes. Following the 1 hour 
incubation, the medium was carefully removed from the adhered cells and replaced with a 
FBS-Agarose solution.  
 
A solution of ESF 921 medium with 10% (v/v) fetal bovine serum (FBS; Invitrogen) was 
prepared and filter sterilised using a 0.45 µM pore filter. For each well 7 mL of 10% FBS and 
7 mL of 1.5% SeaPlaque™ agarose (Lonza) was pre-heated to 40 °C – 42 °C. A 1:1 mixture 
of 10% FBS:1.5% Agarose was prepared and 2 mL of this replaced the medium in each well. 
The mixture was allowed time to set, approximately 20 minutes, before adding 1.5 mL of 
ESF 921 media and 100 µg.mL-1 of penicillin-streptomycin. The plate was incubated in a 
27 °C incubator (without shaking) for 3 to 5 days. 
 
To calculate the viral titre the number of viral plaques per well was determined. Each well 
was stained with 100 µL of (1 ×) Neutral Red stain for 2 hours, allowing for identification of 
viral plaques. Subsequently, the medium was carefully removed from each well and then 
plaques were counted in each well. This allowed the calculation of the number of plaque 
forming units per mL (pfu.mL-1) for the P3 viral stock.      
2.5 General protein methods 
2.5.1 SDS-polyacrylamide gel electrophoresis 
Polyacrylamide gels used in this study were home-made gradient gels (12%–18%). Gels were 
prepared in batches of 10 gels using a Hoeffer Scientific Instruments (HSI) multiple gel 
caster, Bio-Rad Model 385 gradient former and Pharmacia peristaltic pump P-1. Initially 
using the gradient former and peristaltic pump the resolving layer of the gels were cast using 
the Low % and High % solutions, followed by the stacking layer using the Stacking solution 
(Table 2.2). Gels were produced following the general method (Hames, 1998) and stored at 





Table 2.2 Solutions used in the synthesis of SDS-PAGE gels. 
Low % solution High % solution Stacking solution 
Component Amount per 
30 mL 
Component Amount 
per 30 mL 
Component Amount 
per 30 mL 
40% 
Acrylamide 
7.5 mL 40% 
Acrylamide 




HCl pH 8.8 
7.5 mL 1.5 M Tris-
HCl pH 8.8 
7.5 mL 0.5 M Tris-




300 µL 10% (w/v) 
SDS 
300 µL 10% (w/v) 
SDS 
300 µL 
- - 60% (v/v) 
Glycerol 
5 mL - - 
- - Bromophenol 
blue 
210 µL Bromophenol 
blue 
10 µL 
TEMED 15 µL TEMED 15 µL TEMED 25 µL 
10% APS 150 µL 10% APS 150 µL 10% APS 150 µL 
 
Prior to resolving a protein sample via SDS-PAGE the samples were mixed with 2 × sample 
buffer. The 2 × sample buffer consisted of 25 mM Tris-HCl, 12.5% (v/v) glycerol, 0.5% 
(w/v) SDS, 0.005% (w/v) bromophenol blue and 50 mM 1,4-diothiothreitol (DTT). 
 
Non-reducing sample buffer consisted of the same components excluding the reductant DTT. 
These 2 × sample buffers were typically mixed with a protein sample in a 1:1 ratio, with the 
exception of crude mixtures which were mixed in a 1:5 sample to sample buffer ratio. The 
crude mixtures were also boiled at 95 °C for 5 minutes after mixing with the 2 × sample 
buffer and before loading in order to aid denaturation.     
 
PAGE was run using a running buffer that consisted of 2.5 mM Tris-HCl, 19.2 mM Glycine, 
0.1% (w/v) SDS at a current of 220 V for 55 minutes. Generally, the resulting gels were 
stained using Coomassie brilliant blue [50% (v/v) methanol, 10% (v/v) acetic acid, 0.1% (w/v) 
Coomassie Blue R-250] for 15–30 minutes, whilst constantly rocking. Subsequently the gels 
were rinsed with distilled water and destained with a destaining solution [40% (v/v) 
methanol, 10% (v/v) acetic acid]. Stained gels were imaged using ImageScanner III™ 
(GE Healthcare).  
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2.5.2 Western blot analysis 
Certain experiments during this study were analysed by immunoblotting after resolution by 
SDS-PAGE (Section 2.5.1). Following electrophoresis, the proteins were transferred from the 
polyacrylamide gel onto a Amersham™ Protran™ 0.46 µM nitrocellulose blotting membrane 
(GE Healthcare) using either a HSI TE Series Transphor Electrophoresis Unit (wet) or a 
Bio-Rad trans-blot turbo transfer system (semi-dry). Prior to transfer the polyacrylamide gel, 
nitrocellulose membrane, filter papers (Whatmann), and sponges were soaked in a cold (4 °C) 
Transfer buffer [25 mM Tris-HCl, 192 mM glycine and 10% (v/v) methanol] and then 
assembled into the appropriate cassette for either wet or semi-dry transfer. All washes and 
incubation in the western blotting process were performed on a Stuart SRT analogue roller 
mixer (Sigma) at either room-temperature or 4 °C, unless otherwise stated.  
2.5.2.1 Wet transfer  
Wet transfer involved assembling the cassette, enabling the transfer of proteins from the gel 
to the nitrocellulose membrane. Once assembled the cassette was submerged in Transfer 
buffer in the correct orientation within the wet-transfer system. The transfer process was 
performed at a constant 100 V, 400 mA for 1.5 hours, with a continuous flow of water 
through the system to cool.  
2.5.2.2 Semi-dry transfer  
Semi-dry transfer again involved assembly of the cassette, ensuring that the gel and 
nitrocellulose membrane are in the correct orientation. Once assembled the cassette is simply 
inserted into the semi-dry transfer system. The transfer is performed at a constant 100 V, 
200 mA for 30 minutes.  
2.5.2.3 Western-blot processing  
Post-transfer the nitrocellulose membrane was blocked with 10 mL of 5% (w/v) Bovine 
Serum Albumin (BSA) solution, diluted in Tris-buffered saline solution [TBS; 10 mM 
Tris-HCl and 100 mM NaCl]. This blocking step was performed for 1 hour at room 
temperature. Subsequently, the membrane was washed with three separate 10 mL washes of 
Tris-buffered saline + Tween-20 solution [TBST; 10 mM Tris-HCl, 100 mM NaCl and 0.1% 
(v/v) Tween-20]. The membrane was then incubated for 16 hours with the primary antibody, 
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diluted in 5 mL of a 1% (w/v) BSA in TBS solution. Incubation in the primary antibody was 
performed at 4 °C. After incubation with the primary antibody the membrane was again 
subject to three 10 mL washes of TBST. The appropriate secondary antibody diluted in 5 mL 
of a 1% BSA in TBS solution was incubated with the membrane for 1 hour at 
room-temperature, protected from light. Following this the previous wash step was repeated 
with TBST. Finally using the washed membrane western blot images were acquired using an 
Odyssey Fc (Li-COR) imaging system. The primary antibody used in this study was mouse 
monoclonal anti-His6 antibody (GE Healthcare) used at 1:5000 and the secondary antibody 
was an 800CW-conjugated goat polyclonal anti-mouse (Li-COR) used at 1:10000. 
2.5.3 Determination of protein concentration 
Determining the protein concentration in specific samples was performed by measuring the 
absorbance of the sample at 280 nm (A280), using the Nanodrop™ ND-1000 
spectrophotometer. This absorbance was adjusted using the extinction coefficient of the 
protein in the sample, calculated from the primary amino acid sequence of the protein of 
interest by Expert Protein Analysis System (ExPASy) (Artimo et al., 2012).  
 
For certain procedures in the purification process, it was required that the protein sample be 
concentrated to a specific volume. Concentration was achieved via centrifugation of the 
sample in a Microsep™ Advance Centrifugal Device (PALL) with a molecular weight cut-off 
(MWCO) below that of the protein being concentrated. Centrifugation was performed at 
4,000 × g (4 °C) for varied lengths of time until desired volume was achieved.  
2.5.4 Protein expression via bacterial cell culture 
Transformation of E. coli strain BL21 (DE3) was performed via the addition of 
approximately 25 ng of sequence confirmed recombinant plasmid (Section 2.3.4) to 20 µL of 
competent BL21 (DE3) cells. The rest of the transformation procedure was performed as 
detailed in 2.3.4. Colonies from the agar plate incubated O/N were resuspended in 3 mL of 
sterile LB. This resuspension was used to inoculate either 100 mL (small-scale) or 1 L 
(large-scale) of sterile LB at 1:1000 (e.g. 100 µL of resuspension used to inoculate 100 mL of 
LB), supplemented with appropriate antibiotics (Section 2.3.3). The inoculated culture was 
incubated at 37 °C, 215 rpm, until the optical density at 600 nm (OD600) reached 0.6–0.8. 
Once the OD600 was within this range the culture was transferred into an 18 °C, 200 rpm 
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incubator, where it was allowed to acclimatise for 45 minutes. Once acclimated the culture 
was induced with the addition of 200 µM IPTG and incubation at 18 °C, 200 rpm was 
continued O/N.  
2.5.4.1 Harvesting bacterial cell culture 
Harvesting of the culture after O/N incubation varied depending on the culture size. For a 
small-scale culture harvesting was performed via centrifugation at 4,000 × g (4 °C) for 20 
minutes. The resulting supernatant was discarded and the pellet resuspended in 1.2 mL of 
freeze buffer [300 mM NaCl, 20 mM Tris-HCl pH 8.0]. The resuspended sample was stored 
at –20 °C until further processing was performed. For a large-scale culture harvesting was 
performed via centrifugation at 4,000 × g (4 °C) for 30 minutes. The resulting supernatant 
was discarded and the pellet resuspended in 10 mL of freeze buffer [150 mM NaCl, 50 mM 
Tris-HCl]. The resuspended sample was stored at –20 °C until further processing was 
performed.     
2.5.4.2 Bacterial cell lysis  
Lysis of the culture after harvesting also varied depending on the culture size. Resuspended 
small-scale samples were thawed and 1.8 mL of Purification Buffer [300 mM NaCl, 50 mM 
Tris-HCl, 10 mM imidazole, 10% (v/v) glycerol, 10% (w/v) sucrose] was added. 
Approximately 166 µg.mL-1 of lysozyme (Chicken egg, Hampton Research) and 3 µg.mL-1 
of DNase (Applichem) were also added before incubating the sample on ice for 15–20 
minutes. Cells were lysed via sonication for a 1 minute period of pulsed sonication at 35% 
amplitude, using the Sonics VibraCell™ sonicator system (Sonics & Materials). Following 
lysis, separation of the insoluble cellular debris from the soluble protein fraction in the 
sample was accomplished via centrifugation at 14,000 × g (4 °C) for 15 minutes.  
 
Resuspended large-scale samples were thawed and supplemented with Purification Buffer to 
the volume of approximately 30 mL. The same concentrations of lysozyme and DNase 
mentioned above were added to the sample, which was then incubated on ice for 15–20 
minutes. Cells were lysed via sonication for 2 minutes (2 × 1 minute periods of pulsed 
sonication at 70% amplitude, using the Sonifier™ Cell Disruptor sonicator system (Branson 
Sonic Power Co.). Following lysis, separation of the insoluble cellular debris from the 
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soluble protein fraction was accomplished via centrifugation at 14,000 × g (4 °C) for 30 
minutes. 
 
The clarified supernatant (soluble fraction) from either culture size was transferred for further 
processing, whilst the pellet (insoluble fraction) was discarded. Five µL samples of both the 
insoluble and soluble fractions were collected and analysed as crude mixtures via SDS-PAGE 
(Section 2.5.1).       
2.5.5 Protein expression via insect cell culture 
All three insect cell lines previously mentioned were tested for protein expression. Insect cell 
cultures sizes ranged from 20 mL to 50 mL (small-scale) and 100 mL to 2,500 mL 
(large-scale). All insect cell cultures were infected using P3 viral stocks (Section 2.4.6). All 
cultures irrespective of size, were plated prior to infection so that a concentration of 
approximately 1 × 106 cells.mL-1 was reached by the time of infection. The P3 viral stock 
was vortexed and then used to infect the insect cell culture using the viral titre (Section 2.4.7) 
and a chosen multiplicity of infection (MOI), to calculate the amount of viral stock required 
as described in the equation shown: 
𝑎𝑚𝑜𝑢𝑛𝑡	𝑜𝑓	𝑣𝑖𝑟𝑎𝑙	𝑠𝑡𝑜𝑐𝑘 =
𝑐𝑢𝑙𝑡𝑢𝑟𝑒	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	 𝑐𝑒𝑙𝑙𝑠.𝑚𝐿56 ×	𝑣𝑜𝑙𝑢𝑚𝑒	 𝑚𝐿 ×	𝑀𝑂𝐼
𝑣𝑖𝑟𝑎𝑙	𝑡𝑖𝑡𝑒𝑟	 𝑝𝑓𝑢.𝑚𝐿56  
Infected cultures were incubated in a 27 °C shaker for 2 to 4 days, until approximately 50% 
cell death was observed.  
2.5.5.1 Harvesting insect cell culture 
Harvesting varied depending on culture size.  Small-scale cultures were harvested via 
centrifugation at 1000 × g for 5 minutes. The supernatant was discarded and the pellet was 
resuspended in 2 mL of Insect Purification Buffer [150 mM NaCl, 50 mM Tris-HCl pH 8.0, 
10 mM imidazole, and 10% (v/v) glycerol, 2 mM DTT]. The resuspended sample was stored 
at –20 °C until further processing was performed. Large-scale cultures were harvested via 
centrifugation at 1000 × g for 30 minutes. The supernatant was discarded and the pellet was 
resuspended in 10 mL of Insect Purification Buffer. The resuspended sample was stored at – 
20 °C until further processing was performed.  
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2.5.5.2 Insect cell lysis 
Lysis of the culture after harvesting also varied depending on culture size. Resuspended 
small-scale samples were thawed and then lysed via passing the sample through a 25-gauge 
needle 20 times. The lysate was clarified via centrifugation at 14,000 × g for 15 minutes (4 
°C) and the clarified supernatant was collected for further processing. Resuspended 
large-scale samples were defrosted and then diluted to approximately 20 mL using Insect 
Purification Buffer. To the sample, 5 µg.mL-1 of DNase and 100 µL of cOmplete™ 
EDTA-free protease inhibitor cocktail (Sigma) was added. The sample was allowed to 
incubate on ice for 15 minutes, and was subsequently lysed via four passages through the 
Emulsiflex-C3 homogenizer at 20,000 psi (Avestin). Following lysis, the sample was 
centrifuged at 14,000 × g for 30 minutes. The resulting clarified supernatant was carefully 
transferred to a 50 mL tube for further processing. Irrespective of culture size, 5 µL samples 
of both the insoluble and soluble fractions were collected and analysed as crude mixtures via 
SDS-PAGE and western blot analysis (Section 2.5.1/2). 
 
Expression time-courses were performed using small-scale cultures as detailed above with 
two exceptions. Firstly, the cultures were incubated until they reached > 90% cell death. 
Secondly, a 1 mL sample of the culture was collected every 24 hours post-infection and 
processed via the same method in order to assess protein expression over time.                 
2.5.6 Immobilised metal-ion affinity chromatography (IMAC) 
The continued purification of fusion proteins from the clarified supernatant was performed 
manually using either HIS-Select® HF nickel affinity gel beads (Sigma) or cOmplete™ 
His-Tag purification resin (Roche) in a Poly-prep® chromatography column (Bio-Rad). 
Purification Buffer was used for IMAC of samples from bacterial cell culture, whilst Insect 
Purification Buffer was used for IMAC of samples from insect cell culture. Resin was 
pre-equilibrated prior to purification. Once equilibrated the cell supernatant could be 
introduced to the resin. For the small-scale expressions, the cell supernatant was carefully 
pipetted directly onto the resin in the Poly-prep® column and allowed to flow through, thus 
allowing the interaction between the His6 tag of the fusion protein and the Ni2+ in the resin. 
The cell supernatant from large-scale expressions was added to the equilibrated resin in a 
50 mL Falcon tube. This mixture of supernatant and resin was allowed to incubate for 1–2 
hour at 4 °C on a rotor. Following this incubation, the mixture was centrifuged at 3,500 × g 
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(4 °C) for 10 minutes. The supernatant was discarded as flow-through and the resin was 
resuspended in a 1:1 ratio with Purification Buffer and transferred onto a Poly-prep® column.  
 
With the protein bound resin in the Poly-prep® column for both small and large-scale 
expressions the resin was washed to further remove any non-specific binding and therefore 
improve the purity of the protein yield. Using Purification Buffer the bound resin was washed 
with approximately 5 × the volume of the resin bed (e.g. 10 mL wash for 2 mL of resin). 
Subsequently, bound protein was eluted from the column in a series of elution washes. These 
elution washes were performed with Purification Buffer supplemented with 300 mM 
imidazole (or Insect Purification Buffer supplemented with 300 mM imidazole). Elution 
fractions were collected in Eppendorf tubes. Ten microlitre samples of the elution fractions 
were analysed via SDS-PAGE and/or western blot analysis depending on the construct of 
interest. The protein concentration of these elution fractions was measured 
spectrophotometrically (Section 2.5.3). Elution fractions containing protein were pooled.  
Depending on the future use, the pooled protein sample was usually incubated O/N at 4 °C 
with 1–50/100 (w/w) HRV 3C protease in order to cleave the tag from the fusion protein. 
2.5.7 Size-exclusion chromatography  
Size-exclusion chromatography (SEC) is a common method for separating molecules in 
solution based on size (molecular mass). All SEC in this study was performed using an 
ÄKTA Pure Fast Protein Liquid Chromatography (FPLC) system (GE Healthcare) Prior to 
SEC the protein sample was typically concentrated to between 0.5–1 mL (Section 2.5.3) in 
order to load the sample onto the column via syringe injection. The columns used for SEC in 
this study included the Superdex 75 10/300 GL, the Superdex 200 10/300 GL Increase and 
HiLoad Superdex 75 16/60 (all from GE Healthcare). Columns were equilibrated with a 
variety of SEC buffers, however the most common SEC buffers used consisted of either 
300 mM or 150 mM NaCl, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) and 2 mM DTT. The elution of protein from a column was performed isocratically 
over a single column volume at a constant flow rate that was dependent on the column used. 
The A280 of the eluting solution was monitored in real-time via an inline UV detector. This 
detector allows the identification of eluting proteins in the overall elution profile as they 
appear as peaks in the A280. The UNICORN 7.6 software (GE Healthcare) coupled with the 
ÄKTA FPLC system allows the for the collection and analysis of the metrics gained during 
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SEC, typically presented in the form of a chromatogram. Elution fractions from SEC were 
collected by the ÄKTA FPLC system in a 96-deep well plate in in 0.5 mL fractions. SEC 
peak fractions were analysed via SDS-PAGE (Section 2.5.1). SEC fractions containing the 
greatest concentration/purity of the protein of interest were pooled and depending on the 
situation further concentrated (Section 2.5.3). Finally, the sample of protein was aliquoted 
and snap frozen using liquid nitrogen, before being stored at –80 °C until required.  
 
To evaluate the correlation between elution volume and apparent molecular mass from a 
specific SEC column and SEC buffer, a protein standards experiment was performed. 
Proteins of known molecular mass were separated by SEC, to determine their relative elution 
volumes. The proteins used as standards included; ubiquitin (8.5 kDa), Chymotrypsin 
(25 kDa), and Ovalbumin (42.7 kDa).    
2.5.8 Ion exchange chromatography 
All ion exchange chromatography (IEX) in this study was performed using an ÄKTA FPLC 
system (GE Healthcare). IEX was utilised to improve the purity of protein samples via the 
separation of the target protein from contaminants persisting IMAC. Samples were typically 
loaded using a Sample Pump S9 (GE Healthcare) onto a pre-equilibrated column. The 
columns used for IEX in this study included the 5 mL Resource Q, the 5 mL HiTrap SPHP 
and the 5 mL HiTrap QHP. These columns were equilibrated with a variety of IEX buffers. 
The elution of protein from a column was performed using a linear salt gradient by increasing 
the percentage of high salt buffer (Buffer B) over the course of the elution. Elution fractions 
from IEX were collected by the ÄKTA FPLC system in a 96-deep well plate in 0.5 mL 
fractions. IEX peak fractions were analysed via SDS-PAGE (Section 2.5.1). IEX fractions 
containing the greatest concentration/purity of the protein of interest were pooled and 
depending on the situation further concentrated (Section 2.5.3). Finally, the sample of protein 
was aliquoted and snap frozen using liquid nitrogen, before being stored at –80 °C until 
required. 
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2.6 Purification of proteins used in this study 
2.6.1 Purification of COP1 RING domain 
RING domain constructs were expressed in E. coli BL21 (DE3) as a fusion protein with 
either an N-terminal His6 tag, or an N-terminal His6-MBP tag as specified. Expression via 
bacterial cell culture and subsequent IMAC purification were performed as detailed in 2.5.4/6 
respectively. Selected fractions from IMAC were pooled and incubated O/N at 4 °C with 
HRV 3C protease. Subsequently the protein was concentrated and further purified via SEC 
(Section 2.5.7) using a Superdex 75 10/300 GL pre-equilibrated in a SEC buffer [300 mM 
NaCl, 10 mM HEPES and 2 mM DTT]. Selected fractions from the peak of SEC were 
pooled, concentrated, aliquoted, flash-frozen in liquid nitrogen and stored at –80 °C until 
required.              
2.6.2 Purification of COP1 RING + Coiled-coil domain 
RING + Coiled-coil (RING-COIL) domain constructs were expressed in E. coli BL21 (DE3) 
as a fusion either an N-terminal His6 tag, or an N-terminal His6-MBP tag as specified. 
Expression via bacterial cell culture and subsequent IMAC purification were performed as 
detailed in 2.5.4/6 respectively. Selected fractions from IMAC were pooled and incubated 
O/N at 4 °C with HRV 3C protease. Subsequently the protein was concentrated and further 
purified via SEC (Section 2.5.7) using either a Superdex 75 10/300 GL or a Superdex 200 
10/300 GL Increase pre-equilibrated in a SEC buffer [150 mM NaCl, 10 mM HEPES and 2 
mM DTT]. Selected fractions from the peak of SEC were pooled, concentrated, aliquoted, 
flash-frozen in liquid nitrogen and stored at –80 °C until required.            
2.6.3 Purification of ubiquitin 
Bacterial cell pellets expressing recombinant ubiquitin gifted from Gene Zhu (Sato et al., 
2008) were resuspended in 50 mM ammonium acetate pH 4.5 and 1 mM EDTA. The 
resuspended pellet was lysed via sonication and centrifuged. The resulting supernatant was 
incubated at 60 °C for 1 hour to precipitate contaminants. Following incubation, the sample 
was centrifuged and the supernatant was transferred to a sterile tube. The supernatant was 
then purified via IEX using a 5 mL HiTrap SPHP column (GE Healthcare). Ubiquitin was 
eluted using a linear 25 mL gradient from 0 M to 1 M NaCl. Buffer A [50 mM ammonium 
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acetate, 1 mM EDTA] and Buffer B [1 M NaCl, 50 mM ammonium acetate, 1 mM EDTA]. 
Selected fractions from the peak of IEX were pooled and concentrated. The concentrated 
sample was further purified via SEC using a HiLoad Superdex 75 16/60 column equilibrated 
in 50 mM NaCl and 20 mM HEPES pH 7.6. Selected fractions from the peak of SEC were 
pooled, concentrated, aliquoted, flash-frozen in liquid nitrogen and stored at –80 °C until 
required.                     
2.6.4 Purification of Ube1 
The ubiquitin activating enzyme (E1) Ube1 was expressed in E. coli BL21 (DE3) as a fusion 
protein with an N-terminal His6 tag. Expression via bacterial cell culture and subsequent 
IMAC purification were performed as detailed in 2.5.4/6 respectively. Selected fractions 
from IMAC were pooled and dialysed O/N in 2 L of 20 mM Tris-HCl pH 8.5 and 20 mM 
NaCl. Further purification was achieved via IEX using a 5 mL HiTrap QHP column. The 
column was pre-equilibrated in the same buffer used for dialysis, and a linear 50 mL gradient 
from 0.02 M to 0.5 M NaCl. Buffer A [20 mM Tris-HCl pH 8.5 and 20 mM NaCl] and 
Buffer B [20 mM Tris-HCl pH 8.5 and 500 mM NaCl]. Selected fractions from the peak of 
SEC were pooled, concentrated, supplemented with 2 mM TCEP, aliquoted, flash-frozen in 
liquid nitrogen and stored at –80 °C until required.          
2.6.5 Purification of UbcH5b 
The ubiquitin conjugating enzyme (E2) UbcH5b was expressed in E. coli BL21 (DE3) as a 
fusion protein with an N-terminal His6 tag. Expression via bacterial cell culture and 
subsequent IMAC purification were performed as detailed in 2.5.4/6 respectively. The 
protein was concentrated and further purified via SEC (Section 2.5.7) using a Superdex 75 
10/300 GL pre-equilibrated in a SEC buffer [300 mM NaCl, 10 mM HEPES and 2 mM 
DTT]. Selected fractions from the peak of SEC were pooled, concentrated, aliquoted, flash-
frozen in liquid nitrogen and stored at –80 °C until required.            
2.6.6 Purification of E2-ubiquitin conjugates 
Conjugation of ubiquitin to an E2 requires that a charging reaction must first be performed. 
Different concentrations of E1, E2, ubiquitin and ATP, were incubated for varied lengths of 
time to identify optimal conditions for conjugate formation. The final conditions for synthesis 
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of UbcH5b~ubiquitin conjugate used a 500 µL reaction volume. The variant UbcH5b3CS was 
used as it was more stable than wild-type UbcH5b due to the mutation of three cysteine 
residues to serine. The charging reaction included 50 µM UbcH5b3CS, 100 µM WT ubiquitin, 
approximately 0.6 µM Ube1, 4 mM ATP, and 10% (v/v) of 5 × reaction buffer [250 mM 
HEPES, 25 mM MgCl2, 50 mM phosphocreatine (Sigma), and approximately 3 U/mL 
creatine phosphokinase (Sigma)]. The charging reaction was incubated at 37 °C for 1 hour.  
Subsequently, the UbcH5b3CS ~ubiquitin conjugate was purified via SEC using a DTT free 
Superdex 75 10/300 GL pre-equilibrated in 50 mM NaCl and 20 mM HEPES pH 7.6. 
Selected fractions from the peak of SEC were pooled, concentrated, aliquoted, flash-frozen in 
liquid nitrogen and stored at –80 °C until required.      
2.6.7 Purification of COP1 WD40 domain  
During this study, a concerted effort was contributed to the optimisation of the expression of 
constructs of the COP1 WD40 domain in insect cells. Multiple conditions were varied 
including growth media, growth temperature, MOI etc. The optimised protocol for the 
expression of the COP1 WD40 domain construct (residues 376–731) included large-scale 
expression (400 mL culture size) of T. ni insect cells. Expression via insect cell culture and 
subsequent IMAC purification were performed as detailed in 2.5.5/6 respectively. The 
protein was concentrated and further purified via SEC (Section 2.5.7) using a Superdex 200 
10/300 GL Increase pre-equilibrated in a SEC buffer [150 mM NaCl, 10 mM HEPES and 2 
mM DTT]. Selected fractions from the peak of SEC were pooled, concentrated, aliquoted, 
flash-frozen in liquid nitrogen and stored at –80 °C until required.                 
2.7 Protein analysis methods  
2.7.1 Size exclusion chromatography coupled multiple angle laser light scattering 
(SEC-MALLS)  
Purified COP1 RING domain was analysed using a DAWN 8+ multiple angle laser light 
scattering (MALLS) detector (Wyatt Technology Corp.) and a Waters 410 differential 
refractometer (Millipore) coupled in-line to a Superdex S75 10/300 GL column 
pre-equilibrated in SEC buffer [230 mM NaCl, 10 mM HEPES]. The SEC-MALLS data was 
analysed using ASTRA V software (Wyatt Technology Corp.). Fractions from the peak of the 
chromatogram were also analysed via SDS-PAGE (Section 2.5.1).                         
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2.7.2 High throughput crystallisation screens 
Subsequent to purification, COP1 RING and RING + coiled-coil domain proteins were 
concentrated to a desired concentration (Section 2.5.3) and then used to set up the 
crystallisation condition screens. High throughput screens were performed in a 96-well HRC 
2-well plate (Hampton Research) format. The commercially available 96 reagent 
crystallisation condition screens SaltRx HT™, Index HT™ were purchased from Hampton 
Research, and Morpheus™ and PACT premier™ screens were purchased from Molecular 
Dimensions. The condition trials were performed using the sitting-drop vapour diffusion 
method using the commercial screens mentioned. The setup of these screens was performed 
via the Mosquito® crystallisation robot (TTP LabTech Ltd.), which plated the purified 
protein and crystallisation reagent in ratios of either 1:1, 1:2 or 2:1 across the entire screen. 
Each commercial screen was setup in an identical manner and then the plates were incubated 
at 18 °C in the Rock Imager® 1000 (Formulatrix). The Rock Imager® 1000 facilitated the 
remote analysis of the crystallisation trials via regular imaging of the crystal screens that 
were uploaded to the Rock Maker Web (Formulatrix) database.             
2.8 In vitro assays 
2.8.1 Ubiquitin chain-building assay 
An initial evaluation of the ubiquitin E3 ligase activity of the COP1 RING (residues 126–
208) and RING + Coiled-coil (residues 110–308) constructs, was performed via a chain-
building assay. The COP1 E3 constructs were tested with two E2s; UbcH5b and 
Ubc13/Mms2 (provided by the Day Laboratory). The RING ubiquitin E3 ligase Ark2C 
(provided by the Day Laboratory) was also tested with the same E2s as a positive control. 
The chain-building assay utilised a 10 × reaction buffer consisting of [500 mM NaCl, 
200 mM Tris-HCl pH 7.5, 100 mM ATP, 20 mM MgCl2, and 20 mM DTT]. The final 
volume for each reaction of 10 µL was prepared with a 0.05 µM E1, 25 µM ubiquitin, 5 µM 
E2 component, 7.5 µM E3 component and 10% (v/v) 10 × reaction buffer. A separate 
reaction was prepared for each of the time-points to be collected (0, 5, 10, 20 and 60 
minutes). Once prepared all reactions were incubated at 37 °C until their respective time-
point, at which point the reaction was quenched with sample buffer. Once all the reactions 
had been quenched analysis was performed via SDS-PAGE (Section 2.5.1).       
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2.8.2 Ubiquitin discharge assay 
A single-turnover discharge assay format was employed to compare the COP1 ubiquitin E3 
ligase activity between RING (residues 126–208) and RING + Coiled-coil (residues 126–
308) constructs. Multiple experiment formats were tested in order to optimise the discharge 
experiments including using UbcH5bWT~ubiquitinWT conjugate, UbcH5b3CS~ubiquitinWT 
conjugate and UbcH5b3CS~ubiquitinCy3 conjugate. The conjugate used in the final 
experiments was the UbcH5b3CS~ubiquitinCy3 conjugate, which included a fluorescent label 
(Cy3) covalently linked to the ubiquitin molecule. This facilitated a reliable quantification 
process as the experiment could be resolved via non-reducing SDS-PAGE and then imaged 
using the Odyssey Fc (Li-COR) imaging system. The resulting image was quantified via 
ImageJ™ analysis.  
 
The RING and RING + Coiled-coil constructs were diluted to equal molarity in reaction 
buffer [150 mM NaCl, 10 mM HEPES]. The assay reactions were prepared to a final volume 
of 10 µL containing 5 µM E3 component and an excess of UbcH5b3CS~ubiquitinCy3 
conjugate. A separate reaction was prepared for each time-point to be collected (0, 5, 10, 30 
and 60 minutes). The reactions were all incubated at 37 °C until their respective time-point, at 
which point the reaction was quenched with non-reducing sample buffer. Once all the 
reactions had been quenched analysis was performed via non-reducing SDS-PAGE. Samples 
were visualised using the LI-COR Odyssey Fc (Millennium Science) imaging system at 600 
nm. Using ImageJ™ analysis software band intensities were quantified and the data from 
three independent experiments were plotted as the mean ± S.E.M.             
2.8.3 Fluorescence polarisation of COP1 WD40 domain, TRIB1, TRIB2 and C/EBPα 
Purified COP1 WD40 domain (residues 376–731), TRIB1 (residues 84–372) and TRIB2 
(residues 53–343) proteins were analysed via fluorescence polarisation in conjunction with 
synthesised peptides (Mimotopes) with and without a fluorescein isothiocyanate (FITC) 
fluorophore. A full list of the peptides provided by Mimotopes is provided in Table 2.3. The 
TRIB1 and TRIB2 proteins were provided by Sam Jamieson from the Mace Laboratory. The 
subset of fluorescence polarisation experiment used in this study, is known as a fluorescence 
competition assay. In a fluorescence competition assay the receptor (e.g. COP1 WD40 
domain) and fluorophore bound ligand (e.g. TRIB1-FITC peptide) are kept at a constant 
concentration, whilst a competitor ligand (e.g. TRIB1 protein or TRIB1 peptide) is increased 
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in concentration across reactions. A fluorescence polarisation technique in which the 
fluorophore attached ligand concentration was kept constant and the receptor concentration 
was varied, was used to determine interaction constants between TRIB2 and FITC-C/EBPα. 
Multiple experiment formats were tested in order to optimise the fluorescence polarisation 
experiments including varying concentrations of the multiple components, varying reaction 
volume and varying equipment format (e.g. both 96-well and 384-well microplates were 
tested). The final experimental format involved 30 µL final reaction volumes in a black 
384-well plate (Greiner Bio-One). All reaction included a COP1 WD40 domain 
concentration of 1.5 µM and a TRIB1-FITC concentration of 25 nM diluted in the 
fluorescence polarisation buffer [300 mM NaCl, 10 mM HEPES, 0.5 mM TCEP and 0.02% 
(v/v) Tween-20]. The competing ligands, either TRIB1 protein or TRIB1 peptide 
concentrations were varied from 0 to 20 µM. In one set of reactions C/EBPα peptide was 
included at a concentration of 10 µM. Once all reactions were prepared they were allowed to 
incubate at room temperature for 20 minutes, in order to allow the reactions to reach an 
equilibrium. Subsequently the reactions were measured using the PolarStar (BMG Tech) 
plate reader. The inbuilt analysis software performed the necessary data curation and 
milli-polarisation (mP) values were generated for each reaction. Following this method, the 
data from three independent experiments were obtained and plotted as the mean ± S.E.M 
using Prism 7. The data was subject to non-linear regression analysis using the [inhibitor] vs. 
response parameters within Prism 7.     
Table 2.3. Synthesised peptides used for fluorescence polarisation.  
Peptide ID Peptide sequence 
TRIB1 C-terminal peptide H-SEIGTSDQIVPEYQEDSDI-OH 
FITC-TRIB1 FITC-SEIGTSDQIVPEYQEDSDI-OH 
C/EBPα peptide H-GGICEHETSIDISAYIDPAAFND-OH 




Chapter 3 – Characterisation of the ubiquitin E3 ligase activity of 
COP1  
3.1 Introduction 
This section focuses on investigation of the ubiquitin E3 ligase activity of COP1 and its 
relationship to the oligomeric state. It was hypothesised that the ubiquitin E3 ligase activity 
of COP1 was dependent on oligomerisation, mediated via the coiled-coil domain. To 
examine this hypothesis, the activity and oligomeric state of different length constructs of 
COP1 were investigated using in vitro activity assays and SEC-MALLS analysis.  
3.2 Cloning of the COP1 RING domain 
COP1 RING constructs were generated for the assessment of the relationship between 
oligomeric state and activity in COP1. A schematic of the COP1 RING constructs designed 
and used during this study is shown in Figure 3.1. RING constructs were introduced into 
protein expression vectors via LIC (Section 2.2.2/3). Initially the RING 1 construct (residues 
110–208) was generated as a His6 tagged fusion protein. Expression from this construct was 
assessed in a small-scale expression trial (Section 2.5.4). Expression of the construct was 
partially soluble and the elution fractions from IMAC (Section 2.5.8) were characterised by a 
high proportion of non-specific contaminants (data not shown). Therefore, optimisation 
experiments were performed to improve the solubility and purification of this construct.  
 
A key optimisation experiment was the side-by-side IMAC purification of the RING 1 
construct using two brands of Ni2+ resin. HIS-Select® HF nickel affinity gel beads (Sigma) 
and cOmplete™ His-Tag purification resin (Roche) were assessed for their purification 
Figure 3.1. Schematic of the COP1 RING constructs utilised in this study. The RING 1 and the slightly shorter RING 
2 were cloned from the ‘full-length’ COP1 construct (Appendix C). Both constructs were used in the 
investigation of the relationship between oligomeric state and ubiquitin E3 ligase activity in COP1. The entire 
mammalian COP1 is included for reference.       
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capacity via SDS-PAGE (Figure 3.2). Analysis of the elution fractions demonstrated that 
IMAC using the Sigma resin was superior, determined by the reduction in the number of 
contaminants. Therefore, further purifications of the RING 1 construct were performed using 
the HIS-Select® HF nickel affinity gel beads.  
 
During the process of optimising the expression and purification of RING 1, a His6-MBP 
tagged fusion of RING 1 was generated. The aim of this fusion protein was to improve the 
overall solubility of RING 1, thus improving the yield of this protein. The His6-MBP fusion 
protein did improve overall solubility, however subsequent cleavage of the MBP tag and SEC 
(Section 2.5.9) failed to separate MBP from the RING 1 protein (Figure 3.3). As 
demonstrated by the SDS-PAGE analysis of the SEC elution fractions, the single peak 
spanning from 16 to 17 mL elution volume contained; cleaved MBP (46.8 kDa), a 
contaminant (approximately 23 kDa), and COP1 RING 1 (11.7 kDa). Lack of resolution 
between the MBP tag and RING 1 signified a suboptimal purification, especially due to the 
high concentration of cleaved MBP indicated by the intensity of the band.  
 
Overall, despite the attempts to optimise the expression and purification of the RING 1 
construct, the yield and purity remained suboptimal for the purpose of investigating the 
relationship between oligomeric state and activity. For this reason, a second RING domain 
construct was generated as a His6 tagged fusion protein.  
 
Figure 3.2. Trial purification of RING 1 using Sigma or Roche Ni2+ resin. The elution fractions from IMAC 
using either HIS-Select® HF nickel affinity gel beads (Sigma) or cOmplete™ His-Tag purification resin 
(Roche) were resolved via SDS-PAGE. The resin used is indicated at the top of the figure above the 
elution fractions. The black box labelled RING 1 is the band in the elution fractions estimated to be the 
RING 1 construct based on molecular mass.       
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The RING 2 construct (residues 126–208) was designed to be 16 amino acids shorter at the 
N-terminus as it was theorised that these amino acids contributed to the insolubility of the 
previous construct, based on amino acid sequence analysis by the JPred 4 Protein Secondary 
Structure Prediction Server (Drozdetskiy et al., 2015). A side-by-side small-scale expression 
trial of the RING 1 and RING 2 constructs displayed the markedly improved expression of 
the RING 2 construct (Figure 3.4), indicated by the intensity of the construct expression band 
in the soluble fraction. For the RING 1 construct the expression band is indistinguishable 
from the native E. coli proteins, implying a low level of expression. Conversely, the RING 2 
expression band was evident, implying overexpression of this construct. The improved 
expression allowed for a greater proportion of RING 2 binding to the resin in IMAC, and thus 
Figure 3.3. SEC purification of His6-MBP tagged RING 1. A schematic of the purification process resulting in the elution profile of 
the SEC (A) of His6-MBP tagged RING 1 and the corresponding SDS-PAGE analysis of the SEC elution fractions (B). The 
schematic outlines the purification process prior to SEC. The elution profile shows the peak in absorbance at 280 nm detected 
by the inline UV detector of the ÄKTA Pure FPLC. The SDS-PAGE analysis displays the purification sample prior to tag 
cleavage (uncleaved), post tag cleavage (cleaved), the sample loaded onto the Superdex 75 10/300 GL column (input), and the 
elution fraction labelled by their respective elution volumes. Molecular mass (kDa) is displayed on the left side. The bands 




a greater purity and yield present in the elution fractions. For RING 1 the amount of this 
construct recovered in the elution fractions is minimal compared to the amount recovered in 
the RING 2 purification. For the reasons detailed above, the RING 2 construct was used for 
the investigation of the relationship between oligomeric state and ubiquitin E3 ligase activity 
in COP1.  
3.3 Cloning of the COP1 RING + Coiled-coil domain 
The RING-COIL constructs, similarly to the RING constructs were generated for 
investigating the oligomeric state and related ubiquitin E3 ligase activity of COP1. A 
schematic of the COP1 RING-COIL constructs that were designed and used in this study is 
shown in Figure 3.5. Initially the COP1 RING-COIL 1 (residues 110–308) construct was 
generated as a His6-MBP tagged fusion protein. The His6-MBP tagged RING-COIL 1 
construct was impeded by the same issue as its RING equivalent, in that the purification 
failed to separate the MBP from the RING-COIL 1 protein (data not shown). Following the 
same logic used in the cloning of a viable RING construct, a second construct RING-COIL 2 
(residues 126–308) was generated with the same N-terminus as the successful RING 2. The 
Figure 3.4. SDS-PAGE analysis of the purification fraction from RING 1 and RING 2 expression 
constructs. The soluble and insoluble fractions were collected from the cell lysates. The flow-
through (FT) fractions were the portion of the cell lysates that did not bind the resin during 
IMAC, and the elution fractions resulted from IMAC. 
Figure 3.5. Schematic of the COP1 RING-COIL constructs utilised in this study. The RING-COIL 1 and the slightly 
shorter RING-COIL 2 were cloned from the ‘full-length’ COP1 construct (Appendix C). Both constructs were 
used in the investigation of the relationship between oligomeric state and ubiquitin E3 ligase activity in COP1. 
The entire mammalian COP1 is included for reference.       
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expression of this construct was again superior to that of its predecessor and therefore 
RING-COIL 2 was used for the continued investigation of COP1 ubiquitin E3 ligase activity.  
3.4 Investigation of the COP1 oligomeric state 
The oligomeric state of the COP1 RING domain was examined using the purified RING 2 
construct at two different concentrations. The concentrations tested were 39 µM and 78 µM. 
RING samples were loaded onto a Superdex 75 10/300 GL column and SEC-MALLS was 
performed (Section 2.7.2). The data collected at 39 µM generated a calculated mass of 
14 kDa, which is in between the theoretical masses of a RING monomer (10.2 kDa) and a 
RING homodimer (20.4 kDa). The data collected at 78 µM generated a calculated mass of 18 
kDa, which is shifted more towards the theoretical mass of a RING homodimer (Figure 3.6).    
A 
B 
Figure 3.6. SEC-MALLS analysis of the COP1 RING domain. Elution profiles of the COP1 RING domain at 
39 µM (A) and 78 µM (B) detected by differential refractive indices (solid lines). The calculated 
molecular masses are represented with circles. The dashed lines indicate the theoretical molecular mass 
of a COP1RING monomer (red) and homodimer (green). The elution volume (mL) is plotted on the x 
axis. The molecular mass (Da) and refractive index (dRI) are shown on the right and left y axes 
respectively.      
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SEC-MALLS analysis suggests that the COP1 RING exhibits a weak dimeric state at 
concentrations of at least 78 µM. The weak dimeric state is indicated by the fact that the 
calculated mass is below the theoretical mass of a RING homodimer. A calculated mass 
between the monomeric and dimeric theoretical masses suggests a heterogeneous population. 
Within a heterogeneous sample, the MALLS calculated mass is a proportional average of the 
monomeric and dimeric molecules. The heterogeneous sample itself is a result of the weak 
dimerisation interaction of the RING domain. At the lower concentration tested, the data 
again suggests a heterogeneous sample of dimeric and monomeric RING species. The greater 
discrepancy between calculated and theoretical mass indicates an equilibrium shift of the 
weak dimerisation interaction towards a monomeric population. Overall, this data suggests 
that the COP1 RING forms a weak homodimer which appears to dissociate as concentration 
decreases.  
 
The oligomeric state of both the RING and RING + coiled-coil domains are indicated by their 
respective elution volumes from SEC (Section 2.5.7). In comparison to the elution volumes 
of the protein standards, both the RING 2 and RING-COIL 2 constructs eluted at volumes 
which indicated a greater molecular mass than that of the dimer for either construct (Figure 
3.7).  The RING 2 protein eluted earlier than the Chymotrypsin standard (25 kDa), indicating 
an apparent molecular mass greater than a RING 2 homodimer (20.4 kDa). The RING-COIL 
Figure 3.7. Comparison of SEC peaks between RING 2 and RING-COIL 2. SEC was performed using a 
Superdex 75 10/300 GL column for both proteins. The SEC chromatography elution profiles shows the 
peaks in absorbance at 280 nm detected by the inline UV detector of the ÄKTA Pure FPLC. The elution 
profile of the RING 2 (red) is scaled to the right y axis, whilst the elution profile of RING-COIL 2 (green) is 
scaled to the left y axis. The elution volumes of the protein standards and their molecular mass are 
indicated along with the approximate void volume of the column.        
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2 protein eluted earlier than the Ovalbumin standard (42.7 kDa), indicating an apparent 
molecular mass greater than a RING-COIL 2 homodimer (43.8 kDa). Overall, this data 
indicates that both the RING and RING + coiled-coil domains of COP1 exists as an oligomer, 
which is at least dimeric.    
3.5 Crystallisation trials of COP1  
Structural characterisation of the COP1 RING and coiled-coil domains, could provide 
valuable information concerning the mechanisms of dimerisation and how it might affect 
ubiquitin E3 ligase activity. This sort of structural characterisation is typically achieved via 
X-ray crystallography. The N-terminal region (RING and coiled-coil) has not been 
crystallised and therefore, no information about potential crystallisation conditions was 
available. Due to this lack of information, a high throughput screen of crystallisation 
conditions was performed in order to identify a suitable condition for crystal formation.  
 
Large-scale expressions of the RING 2 and RING-COIL 1 constructs were performed 
(Section 2.6.1/2). The purification of these constructs via IMAC, tag cleavage and subsequent 
SEC provided milligram quantities of protein. The RING 2 protein was concentrated to 
14 mg.mL-1 and RING-COIL 1 to 6 mg.mL-1 (Section 2.5.3). These proteins were used in 
crystallisation condition screens. An example of this process featuring RING 2 is shown in 
Appendix D. Crystallisation conditions were screened in a 96-well HRC 2-well plate format 
(Section 2.7.3). The crystallisation screens were monitored for 2 weeks following the initial 
setup. In the condition screens for both RING 2 and RING-COIL 1, a large proportion of the 
drops featured an amorphous precipitate. The rest of the drops were either completely clear or 
featured a phase separation. A large proportion of the drops in the RING-COIL constructs 
screens formed an amorphous precipitate immediately after being plated. This indicated that 
the concentration of RING-COIL utilised may have been too high to induce crystallisation. 
Overall no preliminary crystals were identified for either construct.  
3.6 In vitro activity assays for characterising the ubiquitin E3 ligase activity of 
COP1 
Investigation of the capacity of COP1 to catalyse ubiquitin transfer was performed via two 
types of in vitro activity assay—ubiquitin chain-building assays and ubiquitin discharge 
assays (Section 2.8.1/2). 
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The initial characterisation of ubiquitin E3 ligase activity was performed via a chain-building 
assay involving both the RING 2 and RING-COIL 1 constructs (Section 2.8.1). Assessment 
of activity was performed with the partner E2 enzyme, UbcH5b. The ubiquitin E3 ligase 
Ark2C was used as a positive control due to its documented activity with UbcH5b (Wright et 
al., 2015). Assay samples were resolved via SDS-PAGE, allowing for comparison of the 
ubiquitin E3 ligase activity between the RING and RING-COIL constructs, and against the 
Ark2C positive control (Figure 3.8). The ubiquitin E3 ligase activity of a given ubiquitin E3 
ligase is assessed via the appearance of di-ubiquitin and other higher number polyubiquitin 
species over the course of the assay. For example, in as little as five minutes there are a 
number of polyubiquitin species apparent in the Ark2C reaction, that were not present at time 
zero. The generation of polyubiquitin species indicates that Ark2C is facilitating the transfer 
of ubiquitin from the UbcH5b~ubiquitin conjugate and building a polyubiquitin chain. 
  
Figure 3.8. Ubiquitin chain building assay of COP1 RING and RING-COIL constructs. A schematic of the ubiquitin 
chain-building reaction occurring in the assay is displayed (A). Assay reactions were quenched at time points 
0, 5, 10, 20, and 60 minutes with sample buffer. Reactions were resolved via SDS-PAGE and stained with 
Coomassie Blue (B). The positions of the ubiquitin (Ub), E1 activating enzyme (E1), UbcH5b, Ark2C, RING, 
and RING-COIL are labelled. The arrow represents the position of polyubiquitin species generated over the 




Analysis of this assay result reveals that in comparison to the Ark2C positive control, the 
intrinsic ubiquitin E3 ligase activity of the COP1 RING domain is minimal. There is no 
formation of polyubiquitin species at the early stages of the assay. At the latest stage of the 
assay (60-minute time point) there does appear to be a minimal amount of polyubiquitin 
species formation. This result demonstrates that the COP1 RING domain has little to no 
intrinsic ubiquitin E3 ligase activity and alone is not sufficient for ubiquitin E3 ligase 
activity.  
 
Conversely, polyubiquitin species are apparent from 10 minutes onwards in the COP1 
RING-COIL assay. The generation of polyubiquitin species demonstrates that the COP1 
RING + coiled-coil domain exhibits intrinsic ubiquitin E3 ligase activity. Therefore, in 
comparison to the lack of activity observed in the RING domain samples, the increase in 
activity indicates that both the RING and coiled-coil domain are required and sufficient for 
the ubiquitin E3 ligase activity of COP1. In comparison to the activity observed from Ark2C 
the RING-COIL construct is inefficient, indicated by the increased interval before 
polyubiquitin species appeared and the relative abundance of polyubiquitin species apparent 
in the Ark2C samples.  
 
Ubiquitin chain-building assays were also used to characterise the ubiquitin E3 ligase activity 
of COP1 with the partner E2 enzyme Ubc13/Mms2. The equivalent COP1 constructs as those 
used to test UbcH5b were also used to test the activity with Ubc13/Mms2. Assay samples 
were resolved via SDS-PAGE, allowing for comparison of the ubiquitin E3 ligase activity 
between COP1 constructs, and against the Ark2C positive control (Appendix E). The results 
of the chain-building assay with Ubc13/Mms2 showed minimal activity with either COP1 
construct. Due to only minimal activity being observed and the propensity for Ubc13/Mms2 
to build free ubiquitin chains without the activity of a ubiquitin E3 ligase, UbcH5b was 
chosen as the E2 enzyme with which to perform further analyses.   
 
The disadvantage of the chain-building assay format is that the differing number of lysine 
residues between E3 components can affect the apparent ubiquitin E3 ligase activity if 
auto-ubiquitylation is occurring. The presence of auto-ubiquitylation is indicated by the 
decreasing intensity of the E3 component band, corresponding to the appearance of the 
polyubiquitin species. This can be observed in the Ark2C sample, as the band indicated as 
Ark2C diminishes over the assay period. However, due to the fact that the number of 
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substrate lysine residues available could vary between different ubiquitin E3 ligases, 
auto-ubiquitylation assays can be biased. Therefore, it was important to assess the ubiquitin 
E3 ligase activity of COP1 via a separate method.  
 
The second method used for assessing ubiquitin E3 ligase activity was ubiquitin discharge 
assays (Section 2.8.2). The discharge assays were performed using the RING 2 and RING-
COIL 2 constructs, and UbcH5b3CS~ubiquitinCy3 conjugate. Assay samples, including a 
negative control which omitted the E3 component were resolved via non-reducing SDS-
PAGE (Figure 3.9).  The resulting image was used in a quantification process using ImageJ™ 
software. This quantification involved normalising the intensity of the conjugate band at the 
zero time point as 100% conjugate, then measuring the change in intensity of the conjugate 
band over the assay period. As a ubiquitin E3 ligase facilitates the discharge of ubiquitinCy3 
from the conjugate, the decrease in the percentage of conjugate over the assay period is 
proportional to its ubiquitin E3 ligase activity. The negative control accounted for the 
spontaneous breakdown and discharge of the conjugate in the absence of any ubiquitin E3 
ligase activity. This analysis was performed on three independent experiments and the data 
was analysed and plotted as the mean ± S.E.M (Figure 3.10). There is a significant difference 
Figure 3.9. Ubiquitin discharge assay of COP1 RING and RING-COIL constructs. A schematic of the conjugate 
discharge reaction occurring in the assay is displayed (A). Assay reactions were quenched at time points 0, 
5, 10, 30, and 60 minutes with non-reducing sample buffer. Reactions were resolved via SDS-PAGE and 
imaged using an Odyssey Fc imaging system at 600 nm (B). The position of the UbcH5b3CS~ubiquitinCy3 




in the percentage of conjugate over time between the RING and RING-COIL constructs. The 
RING assays are overall not significantly different to the negative control, in which discharge 
is observed in the absence of any ubiquitin E3 ligase activity. Conversely, the RING-COIL 
assays were significantly different from both the RING and negative control. The rapid 
decline in the percentage conjugate over time indicates the discharge of the conjugate via the 
ubiquitin E3 ligase activity of the RING-COIL construct. This supports the conclusion that 
the RING and coiled-coil domain are both required for the ubiquitin E3 ligase activity of 
COP1.   
Figure 3.10. Averaged percentage conjugate discharged by RING and RING-COIL constructs over a 60-
minute period. The percentage conjugate was normalised to the intensity of the conjugate band at 
time zero and presented as the mean of three independent experiments. The error bars represent 
the S.E.M. of the independent experiments.    
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Chapter 4 – Investigation of the COP1 WD40 domain interactions 
4.1 Introduction 
This section focuses on demonstrating the investigation of the interaction between the COP1 
WD40 domain, TRIB1, and C/EBPα. It was hypothesised that the binding of C/EBPα to 
TRIB1 induces conformational changes in TRIB1, facilitating the interaction between the 
WD40 domain of COP1 and the TRIB1 free C-terminal. To examine this hypothesis, the 
effect of C/EBPα on the interaction between the COP1 WD40 domain and TRIB1 was 
investigated via fluorescence polarisation assays.   
 4.2 Cloning of the COP1 WD40 domain  
Several constructs were generated to produce the COP1 WD40 domain, to investigate the 
interactions between the COP1, TRIB1, and C/EBPα. A schematic of the COP1 WD40 
domain constructs designed and used during this study is shown in Figure 4.1.  
COP1 WD40 domain constructs were generated for expression in insect cells (Section 2.6.7). 
Initially the ‘full-length’ COP1 (residues 110–731) and WD40 1 (residues 351–731) 
constructs were assessed in the SF21 insect cell line. Neither construct exhibited substantial 
levels of expression or solubility (Figure 4.2), despite optimisation (Section 4.3). During this 
project, a study published by Uljon et al. (2016) successfully expressed the COP1 WD40 
domain for crystallisation studies in an insect cell expression system. Therefore, a second 
WD40 domain construct (WD40 2; residues 376–731) was generated based on the construct 
used by Uljon et al. (2016). Initial expression trials of WD40 2 in SF21 cells revealed that, 
similar to WD40 1 expression was entirely insoluble (Figure 4.3). However, through 
Figure 4.1. Schematic of the COP1 WD40 domain constructs utilised in this study. The WD40 1 and WD40 2 
constructs were cloned from the ‘full-length’ COP1 construct (previously cloned by Dr Peter Mace). The ‘full-
length’ COP1, WD40 1, and WD40 2 constructs were all expressed via insect cell culture and utilised in the 
investigation of the WD40 interactions. The entire mammalian COP1 sequence is included for reference.     
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extensive optimisation (Section 4.3) WD40 2 was eventually expressed to a practical level for 
purification and subsequent binding studies.    
4.3 Expression and purification of the WD40 domain from SF21 cell culture 
Initial purification of the ‘full-length’ COP1 and WD40 1 constructs from SF21 cell culture 
revealed that the expression of both constructs was predominantly insoluble (Figure 4.2). 
Therefore, a variety of purification buffers were tested in order to assess their effect on the 
protein solubility of the WD40 domain constructs during the purification process. The 
purification buffers tested are detailed in Table 4.1 and the SDS-PAGE analysis of the trial  
purification for WD40 1 is displayed in Figure 4.4. The purification buffer trial provided no 
significant improvement in the solubility of the WD40 1 construct. This can be determined 
Figure 4.2. SDS-PAGE analysis of the purification of ‘full-length’ COP1 and WD40 1 from SF21 insect cell culture. 
The soluble and insoluble fractions were collected from the cell lysates. The flow-through (FT) fractions were 
the portion of the cell lysates that did not bind the resin during IMAC, and the bound fractions were the 
portion of the cell lysates that did bind the resin during IMAC. The molecular mass (kDa) of the bands are 
displayed on the left side. The bands estimated to be ‘full-length’ COP1 and WD40 1 based on molecular 
mass are boxed.    
Figure 4.3. Western blot analysis of the expression of WD40 2 construct in SF21 insect cells. Expression of the 
WD40 2 construct from SF21 cells was analysed via western blotting. A sample of the SF21 insect cells 
pre-purification (whole cell) was analysed alongside the soluble and insoluble fractions collected from 
the SF21 cell lysate. Samples were blotted with a mouse monoclonal anti-His6 primary antibody and an 
800CW-conjugated goat polyclonal anti-mouse secondary antibody. The molecular mass (kDa) of the 
bands are displayed on the left side. The bands estimated to be WD40 2 based on molecular mass are 
boxed and marked.          
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from the SDS-PAGE analysis, as the band estimated to be the WD40 1 construct is 
prominently present in the insoluble fraction for each purification buffer trialed. 
Table 4.1. Composition of the purification buffers trialled for WD40 1 purification. 
 
Overall, the original Insect Purification Buffer components had the best observed ratio of 
soluble to insoluble WD40 1 protein—though still unsatisfactory for continued purification. 
As a result of this trial, all further purifications of COP1 WD40 domain protein were 
performed using the original Insect Purification Buffer. The trial purification of ‘full-length’ 
COP1 is not shown here but the results were equivalent to that of WD40 1, in that overall no 
improvements in solubility were observed. 
 
As previously described, the second WD40 domain construct WD40 2 was designed based on 
a construct that had been shown to be successfully expressed and purified from insect cell 
PBS High Salt Low pH Original insect purification 
Component Concentration Component Concentration Component Concentration Component Concentration 
10 × PBS 
(pH 7.4) 
10 % (v/v) Tris-HCl 
(pH 8) 
50 mM Tris-HCl 
(pH 6.8) 
50 mM Tris-HCl 
(pH 8) 
50 mM 
Glycerol 10 % (v/v) Glycerol 10 % (v/v) Glycerol 10 % (v/v) Glycerol 10 % (v/v) 
Imidazole 10 mM Imidazole 10 mM Imidazole 10 mM Imidazole 10 mM 
DTT 2 mM DTT 2 mM DTT 2 mM DTT 2 mM 
- - NaCl 300 mM NaCl 150 mM NaCl 150 mM 
Figure 4.4. SDS-PAGE analysis of the optimisation of WD40 1 purification protocol. Multiple variation of insect 
purification buffers were trialed including; phosphate buffered saline (PBS), High salt, Low pH, and the 
original insect purification buffer (Table 4.1). The soluble and insoluble fractions were collected from the 
cell lysates. The molecular mass (kDa) of the bands are displayed on the left side. The bands estimated to be 
WD40 1 based on molecular mass are boxed and labelled.    
 49 
culture by Uljon et al. (2016). Therefore, a sustained effort was made to improve the 
expression from the initial test in the SF21 cell line.  
 
The first variable that was tested in an endeavour to optimise expression of the WD40 2 
construct was the multiplicity of infection (MOI). The MOI is essentially the number of 
infectious viral particles or pfu per insect cell at the time of infection. For example, at 
MOI = 1 there should be a single infectious viral particle per insect cell in a given culture. 
This variable was tested via an expression time course of WD40 2 in SF21 cells. The 
percentage cell death induced by the baculovirus from each culture, over the period of the 
time course was plotted (Figure 4.5). The graph of percentage cell death over the period of 
the time course demonstrates two important points. Firstly, the P3 viral stock of the WD40 2 
construct is definitively virulent, determined by the effect on cell death it has in comparison 
to the negative control (MOI = 0). Figure 4.5 shows that in comparison to the negative 
control each of the MOIs tested, immensely increased the percentage cell death of the insect 
cell culture over time. The fact that the P3 viral stock is virulent is important for the 
propagation of expression of the WD40 domain construct, as the recombinant baculovirus is 
responsible for the repurposing the molecular machinery of the insect cell host for the 
expression of WD40 2. Secondly the percentage cell death graph shows that with the 
Figure 4.5. Graph showing the percentage of cell death over-time post-infection with varied MOI. Cultures of SF21 
cells were infected with the WD40 2 P3 viral stock using a range of MOIs from 0.1 to 10. A negative control 
that omitted the infectious agent (MOI = 0) was included to account for the natural cell death over-time. The 
percentage cell death in each culture was monitored every 24 hours post-infection (Section 2.5.5). Once all 
cultures reached >90 % cell death (with the exception of MOI = 0) the time course was ceased. The legend in 
the top left corner indicates which cell death curve corresponds to which MOI.     
 50 
exception of MOI = 10 there are no substantial changes in the cell death profile of the 
cultures infected with MOIs between 0.1–5. Each of the cultures follow a similar trend of 
increasing percentage cell death per day until day 7 when all cultures reached > 90% cell 
death. The culture infected at MOI = 10 reached > 90 % cell death two days earlier (day 5) 
than the rest of the cultures. The MOI = 10 culture dying more rapidly than the cultures 
infected at a lower MOI is to be expected, as the excess of infectious particles shortens the 
period of time required to infect the majority of the insect cells present in the culture. 
 
In order to accurately infect at varied MOIs, the P3 viral stocks of WD40 domain constructs 
were quantified via the plaque assay method outlined (Section 2.4.7). The viral titres 
calculated for each of the WD40 domain constructs are presented in Table 4.2.        
Table 4.2. Viral titres of WD40 domain constructs calculated by plaque assay. 
Expression construct Calculated viral titre (pfu) 
WD40 1 9.5 × 107 
WD40 2 1 × 108 
‘full-length’ COP1 9.8 × 107 
 
Whole cell samples collected over the period of the time course were analysed via western 
blot to determine if the expression of WD40 2 varied throughout the time course (data not 
shown). Whole cell samples that demonstrated WD40 2 expression were further analysed for 
solubility (Figure 4.6). The western blot analysis of processed samples demonstrated that the 
protein was still entirely insoluble. The analysis of the MOI variable time course indicated 
Figure 4.6. Western blot analysis of the soluble and insoluble fractions from selected days of the MOI time-course. 
Processing of the SF21 cell culture samples from the MOI time course resulted in soluble and insoluble 
fractions that were analysed via western blotting in order to assess the solubility of the WD40 2 construct. 
The MOIs are displayed at the top of the figure, above their respective samples and the days post-infection 
from which those samples were collected. Samples were blotted with a mouse monoclonal anti-His6 
primary antibody and an 800CW-conjugated goat polyclonal anti-mouse secondary antibody. The 
molecular mass (kDa) of the bands are displayed on the left side.         
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that none of the MOIs tested significantly improved the solubility of WD40 2 in SF21 cells. 
Therefore, further optimisation was required in order to successfully express the WD40 2 
construct in SF21 cells. A comprehensive analysis of the other MOIs tested (5 and 10) was 
also performed however the results (not shown here) were equivalent in that solubility of 
WD40 2 was not improved. For all further infections MOI = 1 was used.  
  
The second variable tested in an attempt to optimise expression of WD40 2 was the 
temperature of incubation. Two incubation temperatures were assessed for their effect on 
protein solubility, 22 °C and 27 °C. The percentage cell death induced by the baculovirus 
from each culture over the period of the time course was plotted (Figure 4.7). The graph of 
percentage cell death over the period of the time course indicates that the lower temperature 
for culture incubation of 22 °C is conducive to a prolonged infection. For example, the two 
cultures incubated at 27 °C both reached > 90% cell death by day 6 of the time course whilst 
it took an additional 3 days for the cultures incubated at 22 °C to reach > 90% cell death. It is 
also interesting to note that the negative control culture (MOI = 0) incubated at 27 °C began 
to display increasing cell death after 6 days. The reason for this cell death in a control culture 
Figure 4.7. Graph showing the percentage of cell death over-time post-infection with varied MOI and incubation 
temperature. Cultures of SF21 cells were infected with the WD40 2 P3 viral stock using a MOI of either 0.1 or 1. 
A negative control that omitted the infectious agent (MOI = 0) was included to account for the natural cell 
death over-time. These cultures were incubated at either 27 °C or 22 °C. The percentage cell death in each 
culture was monitored every 24 hours post-infection (Section 2.5.5). Once all cultures reached >90 % cell death 
(with the exception of MOI = 0) the time course was ceased. The legend in the top left corner indicates which 
cell death curve corresponds to which MOI and temperature of incubation. 
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is likely due to the concentration of cells exceeding the capacity of the medium to support 
growth.  
 
Western blot analysis was performed on samples collected from the incubation temperature 
time course (Figure 4.8). The analysis of processed samples from the incubation temperature 
time course demonstrated that neither incubation temperature significantly improved the 
protein solubility of WD40 2. However, differences in protein expression pattern were 
observed between the incubation temperatures tested. Presumably relating to the prolonged 
infection of cultures incubated at 22 °C, the expression of WD40 2 was delayed. This delay 
in expression can be observed in the western blot analysis where at 27 °C the expression of 
WD40 2 is apparent at day 2 whilst expression in cultures incubated at 22 °C is apparent a 
day later. Interestingly the expression of WD40 2 when incubated at 27 °C appears to peak at 
Figure 4.8. Western blot analysis of the soluble and insoluble fractions from the SF21 cultures incubated post-
infection at varied temperatures. Cultures were infected at a MOI of 1 and incubated at either 27 °C (A) or 
22 °C (B). Processing of the SF21 cell culture samples from the incubation temperature time course 
resulted in soluble and insoluble fractions that were analysed via western blotting in order to assess the 
solubility of the WD40 2 construct. Samples were blotted with a mouse monoclonal anti-His6 primary 
antibody and an 800CW-conjugated goat polyclonal anti-mouse secondary antibody. The molecular 




day three and then decline in subsequent days, based on the intensity of the WD40 2 band. 
Due the fact that neither incubation temperature had a significant effect on protein solubility 
it was concluded that for further expressions, cultures would continue to be incubated at 
27 °C.  
 
The third variable that was tested in order to optimise the expression of WD40 2 in SF21 
cells was media composition. Two media compositions were trialed—ESF 921 Protein-free 
insect cell culture medium (Expression Systems), Sf-900™ III Serum Free Medium (Life 
Technologies). The variable of media composition was assessed for its effect on protein 
solubility using SF21 cells infected with the WD40 2 P3 viral stock. Instead of a time course 
the assessment of this variable was performed via western blot analysis of processed sample 
from cultures 3 days post-infection (Figure 4.9). This analysis demonstrated that neither the 
ESF 921 Protein-free insect cell culture medium or the Sf-900™ III Serum Free Medium 
significantly improved the solubility of the WD40 2 construct. Varying the incubation 
temperature (22 °C or 27 °C) of cultures grown in ESF 921 Protein-free insect cell culture 
medium also provided no significant improvement in solubility. 
 
Overall the optimisation of the expression and purification of the WD40 domain constructs in 
the SF21 cell line was ineffective. The tested variables including MOI, temperature of 
Figure 4.9. Western blot analysis of the soluble and insoluble fractions form SF21 cultures grown in either 
Sf-900™ III Serum Free Medium (SF900) or ESF 921 Protein-free insect cell culture medium (ESF). SF21 cell 
cultures were infected with WD40 2 P3 viral stock and grown in either growth medium for 3 days before 
being harvested and processed in order to generate soluble and insoluble fractions. The processed 
fractions were assessed via western blot analysis in order to visualise protein solubility. The ESF medium 
was also assessed at incubation temperatures of 22 °C and 27 °C. The growth medium and incubation 
temperature are specified at the top of the figure above their respective samples. Samples were blotted with 
a mouse monoclonal anti-His6 primary antibody and an 800CW-conjugated goat polyclonal anti-mouse 
secondary antibody. The molecular mass (kDa) of the bands are displayed on the left side. 
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incubation and media composition all provided no significant improvement to the protein 
solubility of the COP1 WD40 domain. The possibility that the issues with the COP1 WD40 
domain solubility may relate to the SF21 cell line specifically seemed feasible, due to the 
extensive optimisation in this cell line providing no improvement. Therefore, the next step 
was to test the expression of the COP1 WD40 domain in different insect cell lines.  
4.4 Expression and purification of the WD40 domain in SF9 and T. ni cell culture 
Initially expression of the WD40 2 construct was compared to between the SF9 cell line and 
the previously used SF21 cell line. A time course was performed expressing the WD40 2 
construct in either cell line and a whole cell sample was collected every 24 hours 
post-infection. The whole cell samples were analysed via western blotting in order to 
evaluate the expression pattern (Figure 4.10). The western blot analysis of whole cell samples 
indicated that SF9 expression of the WD40 2 construct provided an increased amount of 
protein in comparison to SF21. Days 3 and 4 post-infection in the SF9 culture expressed the 
greatest amount of WD40 2 construct, based on band intensity. Based on the result of the 
comparison of expression a trial expression and purification was performed. The SDS-PAGE 
analysis of the trial expression and purification of WD40 2 (Figure 4.11) revealed that the 
expression in SF9 cells provided soluble protein. The presence of soluble protein is suggested 
by the comparison of the band intensity between soluble and insoluble samples. Importantly 
Figure 4.10. Western blot analysis of the whole cell samples from SF9 and SF21 cultures. SF9 and SF21 
cultures were infected with WD40 2 P3 viral stock. Time course samples were analysed via western 
blotting in order to visualise the protein expression compared between the cell lines. Samples were 
blotted with a mouse monoclonal anti-His6 primary antibody and an 800CW-conjugated goat 
polyclonal anti-mouse secondary antibody. The molecular mass (kDa) of the bands are displayed on 
the left side. 
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the soluble expression can be inferred from the fact that protein at the estimated molecular 
mass of WD40 2 (~40 kDa) is present in the elution fractions.  
 
Though SF9 cells had been identified as viable for the expression of WD40 2, additional 
optimisation was performed in an endeavour to further improve expression. Expression in 
SF9 cells was trialed at 22 °C and 27 °C (Figure 4.12). Expression in SF9 cells incubated at 
27 °C post-infection provided an improved quantity of WD40 2 protein in comparison to 
incubation at 22 °C post-infection, based on band intensity. Additionally, the SF9 cells 
Figure 4.11. SDS-PAGE analysis of the trial purification of WD40 2 from SF9 cells. A whole cell and media 
sample were analysed. Soluble and insoluble fractions were collected from the cell lysates. The flow-
through (FT) fraction was the portion of the cell lysate that did not bind the resin during IMAC. The 
IMAC elution fractions were also analysed. The molecular mass (kDa) of the bands are displayed on 
the left side. The band estimated to be WD40 2 based on molecular mass is boxed and labelled.     
Figure 4.12. SDS-PAGE analysis of WD40 2 purification from SF9 cells incubated at varied temperatures. The 
WD40 2 construct was expressed in SF9 cells incubated at either 22 °C (A) or 27 °C (B) post-infection. 
Soluble and insoluble fractions were collected from the cell lysates. The flow-through (FT) fractions were 
the portion of the cell lysates that did not bind the resin during IMAC. The IMAC elution fractions for each 




originally grown in Sf-900™ III Serum Free Medium were adapted to ESF 921 Protein-free 
insect cell culture medium and introduction of cOmplete™ EDTA-free protease inhibitor 
cocktail (Sigma) into the harvested insect cell samples was trialed (data not shown) in an 
endeavour to reduce any possible degradation of WD40 2 protein by host cell proteases. 
Subsequent to optimisation large-scale expression of the WD40 2 construct in the SF9 cell 




Figure 4.13. Large-scale expression of WD40 2 construct via T. ni insect cell culture. Expression of the WD40 2 
construct from 2,500 mL of T. ni cell culture was subsequently purified via IMAC and SEC. SEC was 
performed using a Superdex 200 10/300 GL Increase column. The SEC chromatography elution profile (A) 
shows the peaks in absorbance at 280 nm detected by the inline UV detector of the ÄKTA Pure FPLC. 
Selected fractions from the SEC peaks were analysed via SDS-PAGE (B). The SDS-PAGE analysis included 
the protein sample post-IMAC that was loaded onto the SEC column (input), the insoluble fraction collected 
after lysis of the insect cells, and the SEC elution fraction labelled by their respective elution volumes 
corresponding to the elution profile. The approximate molecular mass (kDa) of the bands are displayed on 
the left side. Post-SEC, selected fractions were pooled and concentrated to generate a working stock of 
WD40 2 protein. The WD40 2 protein working stock was analysed via SDS-PAGE (C). The band estimated 
to be WD40 2 is labelled.         
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expressions of WD40 2 were achieved in SF9 cells. Effective purifications (Section 2.6.7) 
produced a working stock of WD40 2 protein, with which preliminary interaction studies and 
subsequent optimisation was performed.   
 
The insect cells used to express the WD40 domain by Uljon et al. (2016) were High Five 
cells, a clonal isolate derived from a parental Trichoplusia ni cell line. Therefore, it was 
decided that expression of the WD40 domain in a similar cell line could further improve 
expression and purification. However, importation of T. ni cell lines into New Zealand was 
delayed by the Ministry of Primary Industry (MPI) guidelines. After eventual Chief 
Technical Office review and approval, a T. ni cell line was imported. Preliminary expression 
trials of the WD40 2 construct in T. ni cell culture were promising (data not shown). A 
minimal amount of optimisation was performed, similar to that of the SF9 cell line and then 
large-scale expressions were implemented (Figure 4.13). The SEC of WD40 2 was analysed 
via SDS-PAGE. Comparisons between the SEC elution profile and the SDS-PAGE 
demonstrates the purification of the WD40 2 protein from contaminant proteins persisting 
from IMAC purification. Multiple successful purifications from large-scale T. ni cell culture 
provided a working stock of WD40 2 protein, which was used in conjunction with the WD40 
domain protein purified from SF9 cell culture in the subsequent binding studies.  
 
Overall, the expression of the WD40 2 construct was successful via both SF9 and T. ni cell 
culture. T. ni cell culture did not provide a significant improvement in WD40 2 expression 
over SF9 cell culture. Yields of the WD40 2 protein varied between expressions for both cell 
lines, Table 4.3 shows the range of concentrations between the SF9 and T. ni cell lines as 
determined by A280. Though WD40 2 protein yields varied the purity post-purification and 
protein concentration are effectively comparable between cell lines. For this reason, WD40 2 
protein generated from either cell line was used in the binding studies investigating the 
interaction between the COP1 WD40 domain, TRIB1, and C/EBPα. 
Table 4.3. Range of WD40 2 protein yield from SF9 and T. ni cell culture 
Cell line Range of yield per mL of culture (µg) 
SF9 0.45–0.9 
T. ni 0.63–0.93 
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4.5 Fluorescence polarisation                           
Fluorescence polarisation is a technique that is commonly employed to investigate the 
interaction between receptors and their ligands. Fluorescence polarisation can also be used to 
examine certain protein-peptide interactions as they are essentially analogous to a 
receptor-ligand interaction. The theory of fluorescence polarisation is founded on the 
observation that when a fluorescent molecule in solution is excited with plane-polarised light 
the light will remain in the same polarised-plane when emitted from the fluorescent molecule, 
if that molecule remains motionless during the excitation (Perrin, 1926). Unless manually 
immobilised, molecules in solution are subject to Brownian motion and are not motionless. 
Therefore, the molecular motion of a fluorophore suspended in solution during the time 
between the absorption of an excitatory photon and emission of a photon (the fluorescence 
lifetime) affects the plane of the emitted light (depolarisation). Theoretically the plane of 
polarised light is rotated proportionally to the molecular rotation during the fluorescence 
lifetime period as shown in Figure 4.14. More precisely the change in polarisation is related 
to the molecules rotational relaxation time (ρ), a characteristic that itself is a function of 
absolute temperature (T), viscosity (η), the gas constant (R), and importantly molecular 
volume (Vm; equal to molar mass divided by mass density) (Valeur and Berberan-Santos, 
2013). 
 
The typical fluorescence lifetime of a fluorophore is within the order of nanoseconds 
(10-9 seconds). Fluorophores are also usually small in size (less than 1 kDa), meaning 
significant molecular rotation can occur in the fluorescent lifetime. Therefore, quantifiable 
changes in polarisation and depolarisation of plane polarised light are possible. It is also 
Figure 4.14. Schematic of the proportional relationship between molecular rotation of a fluorophore and the 
depolarisation of plane polarised light. The incident polarised light is absorbed by a fluorophore in a specific 
orientation. During the fluorescence lifetime of that fluorophore, significant molecular rotation can occur. The 
molecular rotation changes the orientation of the fluorophore and thus the emitted light is in a different plane 
(depolarised) to the original incident light.    
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possible to produce a significant depolarisation effect when the fluorophore is attached to a 
ligand or peptide as long as it does not greatly increase the molecular weight (generally less 
than 5 kDa). This attachment of a fluorophore to a ligand or peptide forms the basis of 
fluorescence polarisation experiments. If the fluorophore attached ligand interacts with a 
receptor of a significantly greater molecular weight the capacity of the fluorophore to 
depolarise light is greatly diminished. This reduction in depolarisation is the result of the 
apparent increase of the molecular volume of the fluorophore and thus the related increase in 
rotational relaxation time. Practically this can be used to quantify the extent of a specific 
interaction via measuring the extent of depolarisation. 
 
Modern fluorescence polarisation instruments, such as the PolarStar (BMG Tech) used in this 
study, typically function via exciting the fluorophore sample with plane polarised light at the 
appropriate wavelength. The resulting fluorescence is detected by two separate detectors, one 
of which includes a polarising filter of the same orientation as the initial excitation 
polarisation (parallel or polarised signal) and a second that includes a polarising filter 
oriented at 90° to the initial excitation polarisation (perpendicular or depolarised signal). 
Through these detectors the instrument collects two intensity measurements, the parallel 
intensity 𝐼∥  and perpendicular intensity 𝐼< . These intensities are then used to calculate the 






4.6 Investigating the TRIB2 interaction with C/EBPα via fluorescence 
polarisation 
In the process of optimising the fluorescence polarisation experimental format, TRIB2 
(residues 53–343) and C/EBPα (Table 2.3) were used due to the limiting purification 
capabilities of the COP1 WD40 domain. However, in developing this assay with TRIB2 and 
FITC labelled C/EBPα peptide (Mimotopes); a dissociation constant (Kd) was determined. 
The fluorescence polarisation assay held FITC-C/EBPα at a constant concentration, 
supplemented with an increasing concentration of the TRIB2 interaction partner (Section 
2.8.3). The resulting data was analysed using Prism 7 (Figure 4.15). The data at the lower 
TRIB2 concentrations displays the trend that the change in polarisation increases 
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concurrently with the increasing TRIB2 concentration. The data at higher TRIB2 
concentrations suggests that the interaction with FITC-C/EBPα has become saturated, as 
large increases in TRIB2 concentration no longer correlate to increases in polarisation. From 
this data, Prism 7 non-linear regression calculates a Kd for the FITC-C/EBPα and TRIB2 
interaction of 1.04 µM, which is in a comparable range to the Kd calculated by Murphy et al. 
(2015) for the interaction between C/EBPα and TRIB1.    
4.7 Investigation of COP1 WD40 domain interactions via fluorescence 
polarisation 
Fluorescence polarisation was used in order to examine the interaction between the 
C-terminal tail of the pseudo-kinase TRIB1 and the WD40 domain of COP1 and how this 
interaction is affected by the transcription factor and COP1 substrate C/EBPα—which binds 
to the pseudo-kinase domain of TRIB1. Specifically, fluorescence competition assays were 
developed as the format for investigating the binding relationship. Fluorescence competition 
was used based on Uljon et al. (2016), who demonstrated that the affinity of TRIB1 for the 
COP1 WD40 domain changed dependent on whether the entire TRIB1 protein was present or 
just the C-terminal tail. The aim was to recapitulate the change in affinity and investigate 
whether C/EBPα influenced this relationship.  
 
Figure 4.15. Fluorescence polarisation assay of the TRIB2 and FITC-C/EBPα peptide. A constant concentration 
of FITC-C/EBPα peptide was supplemented with increasing TRIB2 concentration. The change in 
polarisation at each TRIB2 concentration was measured. The measurements of change in polarisation are 
plotted (A) as the mean of three independent experiments ± S.E.M. Non-linear regression was used to fit 
the curve. A schematic of the change in polarisation as TRIB2 and FITC-C/EBPα peptide interact (B).    
A B 
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A schematic of the reaction involved in each of the sets of fluorescence competition assays 
and the resulting data, analysed using Prism 7 are shown in Figure 4.16. The graph of the 
change in polarisation relative to the concentration of the competitor peptide demonstrates 
that the competitor peptide interacts with the COP1 WD40 domain and thus displace 
FITC-TRIB1. Equivalent to the data reported by Uljon et al. (2016), the data sets in which 
‘full-length’ TRIB1 protein (residues 84–372) and the C-terminal TRIB1 peptide (Table 2.3) 
were used as the competitors, there is an overall decrease in polarisation as the competitor 
peptide concentration increases. This signifies the ‘full-length’ protein and the C-terminal tail 
of TRIB1 competed with the FITC-TRIB1 for interaction with the WD40 domain. There is a 
greater decrease in the change in polarisation for the C-terminal tail than the ‘full-length’ 
TRIB1 protein, at equivalent concentrations. Indicating that the C-terminal tail competes 
more effectively with FITC-TRIB1 for the interaction with the WD40 domain, consistent 
with the data of Uljon et al. (2016). 
 
Subsequently the hypothesis that the introduction of the C/EBPα peptide may influence the 
observed relationship was tested. The data set that used ‘full-length’ TRIB1 protein as the 
competitor was supplemented with C/EBPα, demonstrated that the addition of C/EBPα does 
in fact influence the interaction between the TRIB1 protein and the WD40 domain. 
Comparison of the data sets with ‘full-length’ TRIB1 protein ± C/EBPα reveals that the 
addition of C/EBPα influences the ‘full-length’ protein to more effectively compete with 
TRIB1-FITC for the interaction with the WD40 domain. The increase in competition is 
observed from the greater decrease in the change in polarisation for the C/EBPα 
supplemented ‘full-length’ protein than the ‘full-length’ protein without C/EBPα, at 
equivalent concentrations—effectively shifting the binding competition curve to the left, 
towards the curve observed for the free C-terminal tail. Therefore, the data suggests that 
C/EBPα shifts the equilibrium of the ‘full-length’ TRIB1 protein towards a free tail state that 





Figure 4.16. Fluorescence competition assay of the COP1 WD40 domain and FITC-TRIB1 C-terminal tail. A schematic 
of the interactions in each of the fluorescence competition assay contexts assessed. The contexts assessed were 
different competing peptides including; ‘full-length’ TRIB1 protein (A; TRIB1), C-terminal tail TRIB1 peptide 
(B; TRIB1 peptide) and the ‘full-length’ TRIB1 protein supplemented with a constant concentration of C/EBPα 
(C; TRIB1 + C/EBPα peptide). A constant concentration of COP1 WD40 domain and FITC-TRIB1 C-terminal 
tail were supplemented with a range of concentrations of the competing peptides. The change in polarisation at 
each competing peptide concentration was measured. The measurements of change in polarisation are plotted 







TRIB1 + C/EBPα 
peptide 
 63 
Chapter 5 – Discussion   
5.1 Overview 
Ubiquitylation is a reversible, covalent, post-translational modification, which is involved in 
a variety of cellular processes including; protein degradation, localisation, altering protein 
function, modulating protein interactions, and signal transduction. The outcome of 
ubiquitylation is dependent on a number of factors including; the target substrate, the number 
of ubiquitin moieties attached (mono- or poly-ubiquitylation), the linkage between ubiquitin 
moieties, and the site of ubiquitylation. Specific interactions between the E2 and E3 enzymes 
regulate the type of ubiquitylation, allowing for a precise mechanism of post-translational 
modification.  
 
Perhaps the most defined aspect of ubiquitylation is its role in maintaining homeostatic 
protein levels via proteasomal degradation. Known as the ubiquitin-proteasome system, 
modification of target proteins with lysine-48 linked polyubiquitin chains facilitates 
localisation to and degradation by the 26S proteasome. The precise regulation of protein 
levels is important in most cellular processes and therefore dysregulation or dysfunction of 
ubiquitylation can result in serious ramifications, including various cancers and other disease 
states. 
 
The mCOP1 has been suggested to regulate the stability of a number of proteins including; 
c-Jun, p53, ETS1 and C/EBPα (Dornan et al., 2004; Wertz et al., 2004; Yoshida et al., 2013; 
Lu et al., 2014). Due to the range of COP1 substrates, dysfunction or dysregulation of COP1 
can lead to disease. For example, COP1 plays a role in a variety of cancers, where there is 
evidence for either an oncogenic or tumour suppressive role depending on circumstance 
(Marine, 2012). Specifically, dysregulation of the COP1 substrate and transcription factor 
C/EBPα has been linked to leukemogenesis in acute myeloid leukemia (AML) (Keeshan et 
al., 2006; 2010). Therefore, the role of COP1 in diseases such as AML invites the 
investigation of the mechanisms through which COP1 functions. To understand COP1 
regulation, it is important to understand both the capabilities of COP1 as a ubiquitin E3 ligase 
and the interactions that COP1 participates in to perform it regulatory role. 
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In the first part of this study the oligomeric state of the COP1 RING domain was 
characterised, and in vitro activity assays using E2~ubiquitin conjugates were employed to 
investigate the capacity of COP1 to promote ubiquitin transfer. Comparable, to similar RING 
ubiquitin E3 ligases such as TRIM25 (Koliopoulos et al., 2016), the COP1 RING domain 
exhibited a weak dimeric interaction in solution. In accordance with the literature, COP1 
possessed ubiquitin E3 ligase activity in vitro with the E2 enzyme UbcH5b. The in vitro 
activity assays also suggested that dimerisation mediated by the coiled-coil domain was 
required for ubiquitin E3 ligase activity (Section 3.6).  
 
In the second part of this study the protein-protein interaction between COP1, TRIB1, and 
C/EBPα, were investigated via fluorescence polarisation assays. We tested the hypothesis 
that interaction between C/EBPα and TRIB1 facilitates the interaction of TRIB1 C-terminal 
tail with the COP1 WD40 domain. The results supported a novel mechanism for the 
regulation of C/EBPα stability via the COP1-TRIB1 interaction (Section 4.7). Additional 
fluorescence polarisation assays alluded to the potential interchangeability of TRIB1/2 in the 
proposed mechanism (Section 4.6).    
5.2 Mechanisms of COP1 regulation 
As discussed (Section 1.8), COP1 has been shown in mammals to interact with and promote 
the ubiquitylation of its substrates in multiple ways (Figure 1.3). To reiterate; COP1 has been 
shown to promote substrate ubiquitylation via its own intrinsic ubiquitin E3 ligase activity 
and direct substrate recruitment, via its own intrinsic activity but through indirect substrate 
recruitment, and via direct substrate recruitment but extrinsic ubiquitin E3 ligase activity 
(Dornan et al., 2004; Wertz et al., 2004; Yoshida et al., 2013). As a result of the multiple 
mechanism through which COP1 regulates a variety of substrates, COP1 can play either an 
oncogenic or tumour-suppressive role dependent on the context (Wei and Kaelin, 2011; 
Marine, 2012). For this reason, it is important to have a substantial understanding of each 
COP1 interaction, as it may help to infer which context dependent role COP1 plays in a 
specific cancer type. 
 
This study focused on understanding the regulation exerted on C/EBPα by COP1, through 
TRIB1. The wider context of the COP1, TRIB1, C/EBPα interaction as well as some of the 
molecular detail has been previously defined (Section 1.9) (Murphy et al., 2015; Uljon et al., 
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2016). Though structural data has revealed that the C-terminal tail of TRIB1 exclusively 
binds either the top face of COP1 WD40 domain or the N-lobe of TRIB1 itself, what induces 
this change remains ambiguous. We hypothesise the binding of C/EBPα to TRIB1, facilitates 
conformational changes in TRIB1 that release the C-terminal tail from the N-lobe allowing it 
to interact with the COP1 WD40 domain as demonstrated schematically in Figure 5.1. 
Understanding the process of COP1 mediated C/EBPα regulation could empower efforts in 
targeting this interaction as a therapeutic response to perturbed C/EBPα levels in AML.  
 
This study also focused on understanding the ubiquitin E3 ligase capacity of COP1. Though 
there is substantial evidence that COP1 does possess intrinsic ubiquitin E3 ligase activity 
(Yoshida et al., 2013), there is minimal evidence on the precise mechanism of this activity. It 
is important to understand this due to the multiple mechanisms through which COP1 can 
promote substrate ubiquitylation, including the capacity to do so without using its intrinsic 
activity, such as in the regulation of c-Jun (Wertz et al., 2004). Therefore, the question 
stands; does COP1 behave equivalently to other RING ubiquitin E3 ligases or does it exhibit 
a novel mechanism for promoting ubiquitin transfer.  
5.3 Expression of COP1 in E. coli 
All COP1 constructs generated during this study were expressed as fusion proteins to 
simplify the purification process. Constructs expressed in bacterial cell culture incorporated 
either a N-terminal His6 tag or a N-terminal His6-MBP tag. The His6 tag functions as an 
affinity tag, facilitating the purification process (Esposito and Chatterjee, 2006). Expression 
of RING 2 and RING-COIL 2 as His6 tagged fusion proteins was particularly successful 
(Section 3.2/4), as purification via IMAC provided significant isolation of the protein of 
Figure 5.1. Schematic of the proposed mechanism for the interaction between COP1, TRIB1 and C/EBPα. 
Binding of C/EBPα to TRIB1 releases the TRIB1 C-terminal tail from its association with the N-lobe. 
The free C-terminal tail is sequestered by the COP1 WD40 domain forming a COP1-TRIB1-C/EBPα 
complex. The formation of the COP1-TRIB1-C/EBPα complex facilitates the promotion of ubiquitin 
transfer to C/EBPα via the intrinsic ubiquitin E3 ligase activity of COP1.     
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interest from the host cell proteins. Purified samples from IMAC only required a single 
auxiliary purification step to achieve the level of purity necessary for crystallisation trials and 
activity assays. The His6-MBP tag provides the solubility enhancing features of MBP 
(Esposito and Chatterjee, 2006). In this study, the His6-MBP tag was used in an effort to 
improve the solubility of the RING 1 construct as prior yields had been suboptimal. The 
method through which MBP facilitates protein solubility is not clear, however it has been 
postulated that MBP acts as an intra-molecular chaperone (Bach et al., 2001; Fox et al., 
2001). The His6-MBP tagged RING 1 did display increased solubility, however expression of 
this fusion protein had multiple issues. Firstly, although a prominent overexpression band 
was produced for His6-MBP tagged fusion proteins a major proportion corresponded to the 
truncated expression of His6-MBP tag alone. Secondly, separation of MBP from the protein 
of interest after cleavage of the tag was unsuccessful. SEC could not separate the cleaved 
MBP from the RING 1 construct, therefore resulting in suboptimal purification. Similar 
issues were encountered with the His6-MBP tagged RING-COIL 1 construct. The inability to 
separate MBP from the protein of interest, indicated that the His6-MBP tag was unsuitable for 
expression of COP1 constructs.  
 
The original RING 1 and RING-COIL 1 constructs begin with the same N-terminal residue 
(serine 110). Directed by amino acid sequence analysis by the JPred 4 Protein Secondary 
Structure Prediction Server (Drozdetskiy et al., 2015), subsequent constructs RING 2 and 
later RING-COIL 2 were generated beginning at serine 126. The 16 amino acids omitted 
were preceding the canonical RING domain and were predicted to be disordered. Removal of 
these 16 amino acids was intended to increase the solubility of the RING 2 and RING-COIL 
2 constructs. Especially in the case of the RING 2 the removal of the 16 N-terminal amino 
acids conferred a significant improvement in solubility. The improvement in solubility was 
likely due to the fact that not only was this segment predicted to be disordered but a number 
of the amino acids omitted were hydrophobic residues, including 4 leucine residues. The 
removal of these hydrophobic N-terminal residues resulted in a more stable and soluble 
construct, as these residues likely contributed to the aggregation of the protein. 
 
In conclusion, the RING and RING + coiled-coil domains of COP1 were successfully 
expressed and purified from E. coli. Optimised expression constructs and purification 
allowed the acquisition of substantial amounts of the RING 2 and RING-COIL 2 via IMAC, 
followed by SEC. As outlined above the RING 2 and RING-COIL 2 were used to investigate 
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the capacity of COP1 as a ubiquitin E3 ligase, as well as for crystallisation trials in an 
endeavour to understand the interactions of the COP1 RING and RING + coiled-coil 
domains.    
5.4 Crystallisation of COP1  
The aim of crystallising the COP1 RING or RING + coiled-coil domain was to provide 
insightful information concerning these domains. If these COP1 domains were inclined 
towards oligomerisation, this conformation could be captured. Crystallisation of a COP1 
oligomer could convey important information about the mechanism of oligomerisation and 
how it may relate to the ubiquitin E3 ligase activity of COP1.  
 
Purified RING 2 and RING-COIL 1 protein were assessed for their crystallisation potential 
(Section 3.5). Neither construct demonstrated crystallisation propensity and therefore efforts 
were concluded. Instead it was decided to perform an extensive biochemical investigation of 
the relationship between oligomerisation and ubiquitin E3 ligase activity in COP1 via 
alternative methods.    
5.5 Investigation of the oligomeric state of the COP1 
It was hypothesised that COP1 existed as a dimer, due to three main observations. Firstly, 
dimerisation is a prevalent mechanism amongst RING ubiquitin E3 ligases such as cIAP, 
RNF4, TRAF6 and TRIM25 for regulating activity (Mace et al., 2008; Yin et al., 2009; Liew 
et al., 2010; Koliopoulos et al., 2016). Secondly, sequence analysis revealed the COP1 RING 
domain shares a high degree of similarity with the RING domains of TRAF6 and TRIM25, 
which also form dimeric species (Yin et al., 2009; Koliopoulos et al., 2016). Lastly, the 
COP1 RING domain is situated adjacent to a coiled-coil domain. Coiled-coil domains are 
frequently associated with oligomerisation, and have been documented as being important for 
the dimerisation and related activity of ubiquitin E3 ligases such as Hsp70-interacting 
ubiquitin E3 ligase CHIP (Nikolay et al., 2003).  
 
This study suggests that the COP1 RING domain forms a homodimer, though the homodimer 
associates through a weak interaction. SEC-MALLS (Section 3.4) using purified COP1 
RING domain was used to gain an accurate measurement of the molecular mass of this 
protein in solution and thus an indication of the oligomeric state. MALLS involves the 
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measurement of the intensity of scattered light from molecules in solution. The intensity of 
the scattered light at a specific angle (θ) [Iscattered (θ)] is directly proportional to a number of 
factors including; molar mass (M), the concentration (c) and the refractive index increment 
(dn/dc) of the solute.  The calculation of molecular mass relies upon an average measurement 
of the intensity of light scattering, obtained from multiple detectors at numerous angles. The 
integration of data from multiple angles improves the accuracy of the molecular mass 
calculation, resulting in a molecular weight value close to the absolute value (Wyatt, 1993).  
 
Though MALLS is regarded as a method for the absolute determination of the molecular 
weight of proteins, the analysis of heterogeneous samples can only generate an average mass 
of all the light scattering molecules present in solution. This is because the MALLS 
calculation relies partly on the molecular mass of the molecules present; different molecular 
species with different molecular masses result in a calculated mass that reflects a proportional 
average of the species present. Therefore, MALLS is coupled successively to SEC in order to 
provide a homogeneous sample (Wyatt, 1993).  
 
The results of the MALLS analysis of the COP1 RING domain indicated two features. 
Firstly, the fact that the calculated masses did not match the theoretical mass of either a 
monomeric or dimeric COP1 RING domain indicated a heterogeneous solution. Therefore, 
the SEC coupled with MALLS was not successful at separating monomeric and dimeric 
COP1 RING species from each other in solution. Secondly, the difference in calculated 
masses at the two concentrations tested indicated that the ratio of monomeric to dimeric 
RING species in solution was dependent on concentration. The higher concentration of RING 
domain tested indicated an increased proportion of dimeric species. However, the monomeric 
species still persisted, indicating a weak dimerisation interaction which appears to dissociate 
at the lower concentration of RING domain tested. Therefore, the SEC-MALLS analysis of 
the COP1 RING domain suggested that this domain exists as a weak homodimer.  
 
To our knowledge this is the first evidence that the mCOP1 RING domain forms a weak 
homodimer in solution. The formation of a RING homodimer indicates that COP1 may 
function similarly to other ubiquitin E3 ligases, in that the dimerisation of the RING domain 
is critical for the ubiquitin E3 ligase activity. The weakness of the dimerisation interaction is 
potentially due to the omission of the coiled-coil domain found adjacent to the COP1 RING 
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domain. As mentioned, coiled-coil domains are often associated with facilitating the 
oligomerisation of proteins. With high sequence similarity to COP1, the ubiquitin E3 ligase 
TRIM25 also includes a coiled-coil domain within proximity of its RING domain. The work 
of Koliopoulos et al. (2016) revealed that the dimerisation of the TRIM25 RING domain was 
mediated by the coiled-coil domain, and that this interaction was crucial for ubiquitin E3 
ligase activity. Importantly Koliopoulos et al. (2016) also showed that the TRIM25 RING 
domain alone had a low propensity for dimerisation. Therefore, comparisons of COP1 and 
TRIM25 suggest that the inclusion of the coiled-coil domain may promote the dimerisation.  
 
An indication that the COP1 RING + coiled-coil protein exists as an oligomer is provided by 
the evaluation of the SEC elution volume in comparison to proteins of known molecular mass 
(Section 3.4). The elution volume of the RING-COIL 2 protein indicates that, in solution this 
protein exhibits an apparent molecular mass greater than 42.7 kDa (closest protein standard). 
Compared to the theoretical molecular mass of 43.8 kDa for a RING-COIL 2 homodimer, 
this result indicates a dimerisation. However, interpretation of this result is only indicative, as 
a number of other factors can also affect a proteins apparent elution volume, such as the 
Stokes stream function. Therefore, to determine whether the RING + coiled-coil domain 
promotes dimerisation, SEC-MALLS analysis of this protein could be performed in a future 
study. Regardless, the AtCOP1 literature demonstrates it exists as a homodimer and that the 
coiled-coil domain is critical for this interaction (Torii et al., 1998). Additionally, Bianchi et 
al. (2003) using HA-tagged full-length human COP1 and a variety of FLAG-tagged COP1 
deletion constructs showed that only constructs containing the coiled-coil domain could be 
co-precipitated—supporting the importance of the COP1 coiled-coil domain in promoting 
dimerisation. 
5.6 Ubiquitin E3 ligase activity of COP1 
Though the evidence presented thus far has supported dimerisation mediated by the 
coiled-coil, it cannot be entirely ruled out that the oligomeric state of COP1 could be 
dependent on an entirely different mechanism such as a post-translational modification like 
phosphorylation—not uncommon amongst ubiquitin E3 ligases (Filipčík et al., 2017). We 
further tested the potential mechanism through in vitro analysis of COP1 constructs with or 
without the coiled-coil domain generated from E. coil, which lack equivalent mammalian 
post-translational modifications.   
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RING type ubiquitin E3 ligases have been shown in previous research (de Bie and 
Ciechanover, 2011) to facilitate the transfer of ubiquitin onto lysine residues within their own 
protein sequence. This phenomenon is known as auto-ubiquitylation, a process which is 
particularly useful for allowing the in vitro evaluation of the specific activity of a ubiquitin 
E3 ligase. A type of auto-ubiquitylation assay known as a ubiquitin chain-building assay was 
used as an initial characterisation of COP1 ubiquitin E3 ligase activity (Section 3.6). 
However, due to the fact that the apparent ubiquitin E3 ligase activity is dependent on the 
number of substrate lysine residues available for ubiquitylation, auto-ubiquitylation assays 
can exaggerate the apparent activity of a ubiquitin E3 ligase. Considering that the RING 
construct used in the chain-building assay had 6 lysine residues compared to the 
RING + coiled-coil construct including a total of 25 lysine residues, there was likely 
considerable bias towards the RING + coiled-coil construct.  
 
The E2 enzyme UbcH5b was tested with COP1 because AtCOP1 has been reported in the 
literature to be capable of auto-ubiquitylation activity in conjunction with UbcH5b (Seo et 
al., 2003). Specifically, AtCOP1 demonstrated ubiquitin E3 ligase activity in vitro in 
conjunction with UbcH5b and therefore it was hypothesised that mCOP1 might share the 
same characteristic. UbcH5 enzymes (including UbcH5b) in general are ideal for in vitro 
assays as they are characterised by low rates of reaction in the absence of a ubiquitin E3 
ligase, but are highly active with a large variety of RING ubiquitin E3 ligases (Stewart et al., 
2016). Ubc13 is an E2 enzyme that forms a heterodimer with the catalytically deficient E2 
variant Mms2. The Ubc13/Mms2 heterodimer specifically builds lysine 63-linked 
polyubiquitin chains (Eddins et al., 2006). Ubc13/Mms2 was tested with COP1 in order to 
contrast the characteristics of UbcH5b. However, Ubc13/Mms2 has the propensity to build 
polyubiquitin chains in the absence of a ubiquitin E3 ligase, making it less ideal for in vitro 
activity assays.  
 
The results of the ubiquitin chain-building assays demonstrated that COP1 appeared to be 
active with both UbcH5b and Ubc13/Mms2. In the assay using Ubc13/Mms2 as the E2 
partner, it is possible that the activity observed was at least partially due to the propensity of 
this E2 enzyme to build polyubiquitin chains without a ubiquitin E3 ligase. Therefore, for 
further in vitro activity assays UbcH5b was employed as its low rate of spontaneous activity 
was considered beneficial for properly quantifying COP1 ubiquitin E3 ligase activity. The 
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ubiquitin discharge assays also implied that there was a difference in the relative activity of 
the COP1 RING if the coiled-coil domain was present in the construct. The preliminary 
chain-building analysis indicated that the inclusion of the coiled-coil domain facilitated the 
ubiquitin E3 ligase activity of COP1. However, as mentioned auto-ubiquitylation assays are 
biased by the number of lysine residues present, and the additional 19 lysine residues in the 
RING + coiled-coil construct likely accentuated its apparent activity. Therefore, to provide a 
clear understanding of the relationship between oligomerisation and activity it was important 
to perform an unbiased analysis of the ubiquitin E3 ligase activity of the COP1 RING domain 
with and without the coiled-coil.  
 
An unbiased analysis of ubiquitin E3 ligase activity was performed using another in vitro 
assay method, known as ubiquitin discharge. The ubiquitin discharge assays demonstrated 
that there is a significant increase in ubiquitin E3 ligase activity with the inclusion of the 
coiled-coil domain. The results of the ubiquitin discharge analysis infer interesting 
information about the relationship between oligomeric state and activity in COP1. As 
postulated COP1 requires dimerisation mediated by the coiled-coil domain in order to 
facilitate ubiquitin transfer. The requirement for dimerisation is indicated by the fact that the 
RING domain alone appears to have minimal activity, whilst the addition of the coiled-coil 
domain significantly increases activity. The SEC-MALLS analysis of the COP1 RING 
domain revealed that this domain existed as a weak dimer, the theory that inclusion of the 
coiled-coil domain would strengthen the dimerisation interaction is supported by the fact that 
inclusion of the coiled-coil domain increases activity. 
 
The relationship between oligomeric state and ubiquitin E3 ligase activity is important 
because E2~ubiquitin conjugates are dynamic molecules that sample ‘open’ and ‘closed’ 
conformations when in the Apo form (Pruneda et al., 2011). RING ubiquitin E3 ligases 
facilitate ubiquitin transfer by sequestering the E2~ubiquitin conjugate in a ‘closed’ 
conformation, conducive for priming the thioester bond for ubiquitin transfer to a target 
substrate (Plechanovová et al., 2012). Often dimerisation of the RING domain is crucial for 
stabilisation of the E2~ubiquitin conjugate in the correct conformation to facilitate transfer. 
Typically, this is achieved by both RING domains forming stabilising contacts with the 
ubiquitin of the E2~ubiquitin conjugate (Dou et al., 2012). This crucial relationship between 
oligomeric state has been observed in a wide range of RING ubiquitin E3 ligases including 
cIAP, RNF4, TRAF6 and TRIM25 (Mace et al., 2008; Yin et al., 2009; Liew et al., 2010; 
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Koliopoulos et al., 2016). However, certain RING domains have been documented as being 
capable of facilitating ubiquitin transfer as a monomer, though other structural components 
independent of the RING domain are crucial for stabilisation in this circumstance (Dou et al., 
2013). Therefore, understanding the relationship between oligomeric state and ubiquitin E3 
ligase activity in COP1 is important in determining its specific mechanism of ubiquitin E3 
ligase activity. The evidence presented thus far suggests that the relationship between 
oligomerisation and activity in COP1, and by extension the mechanism of ubiquitin transfer, 
is similar to other dimeric RING ubiquitin E3 ligases such as TRIM25 (Figure 5.2).  
 
Further confirmation of the relationship between dimerisation and ubiquitin E3 ligase activity 
could be provided by mutagenesis experiments. Mutants of the COP1 RING domain were 
designed for the purpose of inhibiting dimerisation using a homology model based on the 
RING domain of TRIM25. The theory was that inhibiting dimerisation of the COP1 RING 
domain would inhibit the ubiquitin E3 ligase activity. The RING mutants were tested via 
ubiquitin discharge assays, however no significant difference to the wild-type RING domain 
was observed (data not shown). The reason for the lack of change in activity is likely due to 
Figure 5.2. Hypothesis of the relationship between oligomeric state and ubiquitin E3 ligase activity in 
COP1. A schematic indicating that, the activity of COP1 is amplified by increased dimerisation of 
the RING domain, mediated by the coiled-coil domain (A). The dimerisation of the RING domain 
likely increases activity by facilitating stabilising contacts with the E2~ubiquitin conjugate, as 
observed in other RING ubiquitin E3 ligases such as TRIM25 (B) (PDB: 5FER).     
A B 
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the fact that the RING domain alone only exhibited a weak dimeric interaction and possessed 
minimal ubiquitin E3 ligase activity. Therefore, disruption of the already weak dimeric 
interaction had little effect on the already minimal activity of this domain. However, testing 
these mutants in the RING + coiled-coil context would be an ideal experiment for testing 
whether dimerisation was definitively required for ubiquitin E3 ligase activity. Therefore, an 
in vitro analysis of dimerisation mutants in a future study would significantly support the 
theory that dimerisation of COP1 is required for ubiquitin E3 ligase activity.  
 
In conclusion the analysis of COP1 ubiquitin E3 ligase activity via in vitro activity assays, 
demonstrated that COP1 can promote the transfer of ubiquitin via its own intrinsic activity 
and that the capacity to do so relies on the dimerisation mediated by the coiled-coil domain. 
The conclusion that dimerisation is important for the intrinsic ubiquitin E3 ligase activity of 
COP1 is particularly interesting as it may suggest how COP1 exerts its regulatory pressure 
without using its intrinsic activity, such as in the context of c-Jun regulation (Wertz et al., 
2004). In the context of c-Jun regulation COP1 exists as part of the CUL4 ubiquitin E3 ligase 
complex. Though undetermined it is possible that within this complex COP1 is unable to 
dimerise, or else forms a heterodimer with another component of the CUL4 ubiquitin E3 
ligase complex. Thus, the intrinsic activity of COP1 is attenuated and instead it can perform 
its role of directly interacting with c-Jun in order to promote its ubiquitylation by RBX1—
another component of the CUL4 ubiquitin E3 ligase complex.   
5.7 Optimisation of insect cell expression system 
COP1, as previously illustrated is involved in various protein-protein interactions. In A. 
thaliana COP1 (AtCOP1) it is established that such substrate mediating interactions are 
facilitated by the WD40 domain (Yi and Deng, 2005). However, for the mammalian 
homologue there is less extensive evidence. It has been demonstrated that the COP1 substrate 
of interest for this study, C/EBPα is regulated via interaction through TRIB1 to the COP1 
WD40 domain (Uljon et al., 2016). As mentioned, to understand the details of the interaction 
performed by the COP1 WD40 domain it was necessary to express this domain, facilitating 
investigation using binding studies.  
 
Prior to this study, others in the Mace Laboratory trialed the expression of the COP1 WD40 
domain in bacterial cell culture. The results of these trials demonstrated that it was not 
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viable—the details will not be discussed here. The relevant literature indicates that expression 
of the complex structure of WD40 domains is suited to higher order expression systems such 
as insect cells (Kallio and Kursula, 2014; Uljon et al., 2016). Therefore, during this study the 
expression of the WD40 domain was trialed and optimised in insect cells.  
 
Initially the expression of the COP1 WD40 domain was trialed in the insect cell line SF21, 
where it was entirely insoluble (Section 4.3). The solubility of a protein is a complex function 
dependent on numerous variables including environmental factors such as pH, temperature, 
salt concentration; and properties of the protein such as folding, post-translational 
modification, and the physicochemical nature of the protein. Insolubility can also occur as a 
result of the overexpression of a heterologous protein, inducing the formation of inclusion 
bodies in the host cell. Inclusion bodies are essentially large insoluble aggregates of the 
heterologous protein, which may form due to incorrect folding, lack of post-translational 
modification, or simply too great a concentration of the offending protein. Regardless, 
insoluble expression is not productive. There are two main options for solving this issue, 
either attempt protein refolding or optimise expression to provide soluble protein. In this 
study optimisation experiments were performed to develop soluble expression of the COP1 
WD40 domain.    
 
The composition of the buffer used for the insect cell lysis was the first component to be 
optimised. Salt concentration has a major influence on protein solubility. If the salt 
concentration is too low proteins tend to aggregate, but as the salt concentration increases the 
solubility of a protein will also increase—an effect known as ‘salting-in’. The increase in 
protein solubility is provided by the salt counter ions that lower the electrostatic free energy. 
Conversely, at high salt concentrations the profusion of salt ions diminishes their solvating 
capacity, thus decreasing protein solubility (Melander and Horváth, 1977). Additionally, 
protein solubility is affected by pH, depending on the composition of the protein and the 
quantity of ionisable groups. The buffering reagent can also play a role in facilitating protein 
solubility. Therefore, a screen of a variety of buffer compositions were trialed including; a 
high salt concentration of 300 mM NaCl, a low salt concentration of 150 mM NaCl, a pH of 
8.0, a pH of 6.8, a Tris-HCl based buffer, and a phosphate-based buffer. The results of the 
buffer composition screen suggested that none of the tested variables improved the solubility 
of the WD40 domain expressed from SF21 cells. Whilst not exhaustive, due to time 
constraints it was not efficient to continue assessing every possible combination of lysis 
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buffer. Furthermore, the observation that none of the buffer compositions assessed provided 
even a minimal increase in protein solubility, suggested that the protein insolubility may 
originate prior to cell lysis.  
 
Coinciding with the insolubility issues of the WD40 1 construct in SF21 cells, Uljon et al. 
(2016) demonstrated the successful expression of the COP1 WD40 domain via High Five 
insect cell culture. Therefore, a second WD40 domain construct (WD40 2) was generated in 
order to match the construct used by Uljon et al. (2016). In theory if the WD40 2 construct 
had previously been successfully expressed in an insect cell line, it might also successfully 
express in SF21 cells. Unfortunately, this was not the case and initial expression trials of 
WD40 2 were as unsuccessful as WD40 1. However, as stated the WD40 2 had been 
expressed via insect cells before and therefore an extensive optimisation effort was 
undertaken.         
 
The set of variables assessed for their effect on the solubility of the WD40 2 construct were 
aimed at facilitating soluble expression. The effect of MOI on recombinant protein 
expression has been previously studied, and it has been demonstrated to influence protein 
stability—particularly at low MOIs (Radford et al., 1997). Therefore, a range of MOIs were 
assessed for their effect on WD40 domain protein solubility. The MOIs tested ranged from 
0.1, the equivalent of 1 infectious particle per 10 insect cells; to 10, the equivalent of 10 
infectious particles per 1 insect cell. Additionally, the incubation temperature of the insect 
cells post-infection has also been shown to affect recombinant protein expression (Andersen 
et al., 1996), and therefore two temperatures within the suggested optimal range for insect 
cell culture (22 °C and 27 °C) were assessed for their effect on protein solubility. Two 
different compositions of insect cell media from separate companies were also assessed for 
their effect on protein solubility. The variables detailed were assessed for their effect on 
solubility of WD40 2 expressed from SF21 cells via expression time courses and subsequent 
western blot analysis. None of the variables provided a significant improvement in protein 
solubility. Overall, extensive optimisation of the expression of both the WD40 1 and WD40 2 
constructs in SF21 cells provided no improvement in the protein solubility. The fact that none 
of the optimisation experiments improved solubility suggests that the insolubility issue is a 
consequence of an inherent characteristic of the SF21 cell line. For example, perhaps the 
SF21 cell line lacks a chaperone that is proficient in facilitating the correct folding of WD40 
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domains. Therefore, the next approach was to assess expression of the COP1 WD40 domain 
in a separate cell line.  
 
The expression of the WD40 2 construct was tested in two different insect cell lines (Section 
4.4). The cell line SF9, a clonal isolate of the SF21 cell line was tested as well as a T. ni cell 
line comparable to the High Five cells used to express the COP1 WD40 domain (Uljon et al., 
2016). The expression of the WD40 2 construct was assessed in the SF9 cell line initially. 
The T. ni cell line was only attained partway through this study as the importation of this 
species into New Zealand was initially prohibited by the Ministry of Primary Industry (MPI) 
guidelines.  
 
An initial trial expression of the WD40 2 in the SF9 cells was successful in obtaining soluble 
protein. However, in order to provide a suitable amount of protein for binding studies it was 
determined that further optimisation was required. Therefore, expression of the WD40 2 
construct in SF9 cells was trialed with post-infection incubation temperatures of 22 °C and 
27 °C. It was determined that incubation at 27 °C post-infection was preferential for the yield 
of WD40 2 protein. The growth media used for the SF9 cells was also changed and a protease 
inhibitor was introduced, though the effect of these variables were insignificant. Overall, the 
expression of WD40 2 was optimised to a suitable level to facilitate successfully purification 
and production of a working stock of WD40 domain protein for subsequent binding studies.  
Once the T. ni cell line was imported it was observed that comparative yields of the WD40 2 
protein were provided from the large-scale expression of both the SF9 and T. ni cells.  
 
Overall the optimisation of the WD40 domain expression in insect cell culture resulted in 
successful expression and purification of this domain. Though extensive optimisation was 
performed on the SF21 cell line, it was concluded that expression of the WD40 domain was 
not viable in these cells. However, expression in the similar cell line SF9 was viable, 
suggesting that the inability of SF21 cells to express the WD40 domain was cell line specific. 
It was demonstrated that the expression of COP1 WD40 domain was also viable in a T. ni 
cell line, and together either SF9 or T. ni produced protein that could be used for the binding 
studies that sought to investigate the interaction between COP1, TRIB1, and C/EBPα. 
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5.8 Interaction of the COP1 WD40 domain with TRIB1 and C/EBPα 
The COP1 WD40 domain performs the important role of the substrate recruitment domain. 
The WD40 domain in AtCOP1 has been shown to be important for the interaction and 
regulation of a variety of substrates including; HY5, PhyA, CRY1 and multiple others (Ang 
et al., 1998; Yang et al., 2001; Seo et al., 2004). In the mammalian context, the COP1 WD40 
domain has been shown to interact with c-Jun and TRIB1 (Bianchi et al., 2003; Uljon et al., 
2016). The interaction of COP1 with TRIB1 is of particular interest as TRIB1 is not a 
canonical COP1 substrate, but instead acts as a substrate adapter. TRIB1 sequesters the 
transcription factor and COP1 substrate C/EBPα (Yoshida et al., 2013). The interaction 
between COP1, TRIB1 and C/EBPα facilitates the ubiquitination of C/EBPα, however the 
precise mechanism of this interaction is not entirely understood. Research has shown that the 
COP1-binding motif in the C-terminal tail of TRIB1 is sequestered by its own N-lobe in an 
auto-inhibitory fashion (Murphy et al., 2015). When released by an unknown mechanism, the 
TRIB1 C-terminal tail forms a specific interaction with the COP1 WD40 domain (Uljon et 
al., 2016). TRIB1 also specifically interacts with C/EBPα, the detail of which is 
undetermined.  
 
In order to further understands the molecular mechanisms of the interaction between COP1, 
TRIB1, and C/EBPα, fluorescence competition assays were employed (Section 4.5). The 
analysis of the fluorescence competition assays revealed that as previously detailed by Uljon 
et al. (2016) the C-terminal tail of TRIB1 specifically interacts with the COP1 WD40 
domain. The interaction between the C-terminal tail of TRIB1 and the COP1 WD40 domain 
differs if either the ‘full-length’ TRIB1 protein or just a C-terminal tail peptide is used as the 
competitor peptide in the competition assays. The C-terminal tail was more effective at 
displacing the FITC-TRIB1 from the COP1 WD40 domain than the ‘full-length’ TRIB1 
protein. The proposed reason for the difference is that the ‘full-length’ TRIB1 exists in an 
equilibrium in which its C-terminal tail is sequestered by the N-lobe for the majority of its 
population. However, when the C-terminal tail is not sequestered, such as the free C-terminal 
tail peptide it can freely bind to the COP1 WD40 domain. Interestingly the difference in 
interaction suggests that there is an unknown molecular switch or energetic cost that shifts 
the equilibrium and facilitates the release of the TRIB1 C-terminal tail from its auto-inhibited 
state—as the WD40 domain preferentially binds the free C-terminal tail. The molecular 
switch is demonstrated in this work, when the fluorescence competition assay was performed 
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using the ‘full-length’ TRIB1 protein supplemented with C/EBPα. Addition of C/EBPα 
appeared to increase the efficiency of the ‘full-length’ TRIB1 protein in displacing 
FITC-TRIB1 from the WD40 domain. This shift upon the addition of C/EBPα, suggests a 
potential mechanism for the COP1, TRIB1 and C/EBPα interaction. Additionally, a structure 
of TRIB1 with C/EBPα bound to the core pseudo-kinase domain (unpublished data care of 
Dr Peter Mace), shows a drastic change in the position of the ‘activation loop’ in comparison 
to the unbound TRIB1 structure (Murphy et al., 2015), thus demonstrating the 
conformational changes caused by C/EBPα binding (Figure 5.2). In conjunction with the 
fluorescence competition assays, these evidence supports the hypothesis that; the 
conformational changes to TRIB1 brought about by C/EBPα binding, allow the recruitment 
of COP1 via the favourable interaction between the COP1 WD40 domain and the free 
C-terminal tail of TRIB1. 
 
Furthermore, a series of molecular dynamics (MD) simulations were performed by Zheng 
Ruan from the University of Georgia (unpublished data), focusing on the dynamics of the 
TRIB1 C-terminal tail in different contexts (Figure 5.3). Using data from the structure of 
A B 
Figure 5.3. Structure of TRIB1 with and without C/EBPα bound. The structure of TRIB1 with C/EBPα (red) 
bound (A) and the activation loop of highlighted (green) was generated from unpublished data, care of Dr 
Peter Mace (University of Otago). The C-terminal tail is unresolved in this structure. The structure of 
TRIB1 without C/EBPα bound (B) was generated from the data of Murphy et al. (2015) (PDB: 5CEM). 
The C-terminal tail (cyan) is interacting with the N-lobe. The activation loop (green) in the unbound TRIB1 
structure was unresolved, however a poly-alanine loop of equivalent proportions was modelled using Coot. 
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TRIB1 solved by Murphy et al. (2015), the MD simulations were performed using TRIB1 in 
an Apo state, TRIB1 without a substrate bound but the core pseudo-kinase domain 
manipulated to mimic the substrate bound state, and TRIB1 with the C/EBPα substrate 
bound. The MD simulations indicated that the interaction between the C-terminal tail and the 
N-lobe of TRIB1 varied, depending on the interaction of TRIB1 with C/EBPα. In the Apo 
state the C-terminal tail of TRIB1 participates in extensive hydrogen bonding with the β4 
strand of the N-lobe throughout the simulation. This sequestration of the C-terminal tail by 
the N-lobe, agrees with the evidence provided by the fluorescence competition assays in this 
study and the structural data of Murphy et al. (2015). In the Apo state TRIB1 exerts an auto-
inhibitory effect on its own C-terminal tail. Modelled on the unpublished structure of TRIB1 
Figure 5.4. Molecular dynamics simulation of the TRIB1 in different conformational contexts. The upper panel (A) 
shows a snapshot of the molecular detail of the interaction between the C-terminal tail and N-lobe (β4 strand) 
of TRIB1 during the molecular dynamics simulations. The interaction is pictured in the different contexts 
simulated. The contexts included; the TRIB1 structure as obtained via crystallographic methods (PDB: 5CEM), 
the TRIB1 structure with no substrate bound but the core pseudo-kinase domain has been altered to mimic the 
substrate bound state (no substrate), and the TRIB1 structure with the C/EBPα substrate bound (with 
substrate). Hydrogen bonds between the C-terminal tail and the N-lobe are represented by dashed lines. The 
lower panel (B) shows the number of hydrogen bonds formed between the C-terminal tail and the N-lobe of 
TRIB1 over the simulation period for each of the conformational contexts tested. Unpublished data, care of 





bound by C/EBPα previously mentioned, the MD simulation in which the core pseudo-kinase 
domain had been manipulated to represent a substrate bound state demonstrated a decreasing 
amount of hydrogen bonding between the C-terminal tail and the N-lobe. The amount of 
hydrogen bonding decreased until approximately half way through the simulation 
(~500,000 ps) after which, no hydrogen bonding between the C-terminal tail and N-lobe 
occurred. Furthermore, in the MD simulation of TRIB1 bound by C/EBPα, the hydrogen 
bonding between the C-terminal tail and N-lobe was attenuated even faster. The majority of 
the C/EBPα bound simulation was characterised by a lack of hydrogen bonding, therefore 
indicating the release of the C-terminal tail from its auto-inhibition. The MD simulations 
detailed, support the proposed hypothesis that the binding of C/EBPα to TRIB1 induces 
conformational change that facilitate the release of the auto-inhibition of the C-terminal tail.          
 
Previous studies have demonstrated that TRIB2, similar to TRIB1, is associated with the 
regulation of C/EBPα via interacting with COP1 through its C-terminal tail COP1-binding 
motif (Dedhia et al., 2010; Keeshan et al., 2010; Yoshida et al., 2013). In this study, a 
dissociation constant (Kd) of 1.04 µM was calculated from fluorescence polarisation data of 
the interaction between C/EBPα and TRIB2. The Kd suggests a strong interaction, which 
supports the hypothesis that either TRIB1 or TRIB2 may play an interchangeable role as the 
substrate adapter in the mechanism for regulating C/EBPα stability outlined above. This is 
interesting from a biological point of view because though the TRIB1/2 homologues are 
highly similar they differ in their N-terminal regions, purportedly for the purpose of protein 
localisation (Kiss-Toth et al., 2006). Therefore, the interchangeable nature of TRIB1/2 in the 
mechanism for regulating C/EBPα stability, could be a method of providing C/EBPα 
regulation in different cellular environments. Further confirmation of this could be achieved 
by fluorescence competition assays, analogous to those preformed in this study though with 
TRIB2 substituted for TRIB1.       
 
Overall the investigation of the interaction between COP1, TRIB1 and C/EBPα provided 
insightful information about the potential regulatory mechanism. Though it had been 
previously demonstrated that COP1 regulated the stability of C/EBPα via the substrate 
adapter TRIB1, it was ambiguous how the three proteins interacted to facilitate this 
regulation. This study has demonstrated using fluorescence competition assays that the 
binding of C/EBPα to TRIB1 facilitates the release of the TRIB1 C-terminal tail, thus 
 81 
promoting the binding of COP1 to the TRIB1 C-terminal tail. We hypothesise that via this 
mechanism COP1 specifically promotes C/EBPα for ubiquitylation and subsequent 
proteasomal degradation. Thus, COP1 may specifically regulate the stability of C/EBPα in a 
cellular context. Understanding this mechanism is critical if the regulation of C/EBPα by 
COP1 is to be targeted in a therapeutic manner. For example, in the context of AML where 
levels of C/EBPα are often decreased, small-molecule targeting such as have been proposed 
for TRIB2 (Bailey et al., 2015) could aim to inhibit the COP1, TRIB1 and C/EBPα 
interaction thus providing a method for reestablishing C/EBPα levels.  
5.9 Concluding Remarks 
This study has focused on two main aims involving the ubiquitin E3 ligase COP1. Firstly, 
investigating the intrinsic ubiquitin E3 ligase activity of COP1 and its relationship to 
oligomeric state, and secondly the interaction that COP1 is involved in via its WD40 domain 
with the pseudo-kinase TRIB1 and transcription factor C/EBPα. These aims were 
investigated using protein constructs of human COP1 generated from either bacterial or 
insect cell expression systems. The relationship between ubiquitin E3 ligase activity and 
oligomeric state was investigated primarily using in vitro activity assays and SEC-MALLS, 
whilst the interaction with TRIB1 and C/EBPα was investigated using a fluorescence 
polarisation technique known as a fluorescence competition assay.  
 
Investigation of the relationship between the ubiquitin E3 ligase activity and oligomeric state, 
suggested that the RING domain of COP1 formed a weak dimer. However, the RING domain 
alone was not sufficient to promote ubiquitin transfer. Instead dimerisation of COP1 
mediated by the coiled-coil domain adjacent to the ‘catalytic’ RING domain was necessary 
for the ubiquitin E3 ligase activity of COP1. This relationship is common for RING ubiquitin 
E3 ligases, for example TRIM25, another ubiquitin E3 ligase that shares high sequence 
similarity with COP1 exhibits an analogous relationship between activity and oligomeric 
state (Koliopoulos et al., 2016). The conclusion that dimerisation is important for the 
ubiquitin E3 ligase activity of COP1 as this is likely the method through which COP1 
regulates the stability of numerous proteins that it directly interacts with such as p53 and 
ETS1 (Dornan et al., 2004; Lu et al., 2014). Though a substantial starting point, further 
investigation would definitely benefit the understanding of this relationship. For example, 
mutagenesis studies could further support the importance of oligomerisation in relation to 
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ubiquitin E3 ligase activity. Additionally, solving a crystal structure of COP1 in conjunction 
with an E2~ubiquitin conjugate would provide molecular details of the precise mechanism 
through which COP1 facilitates ubiquitin transfer.  
 
Investigation of the interaction between the COP1 WD40 domain and C/EBPα via TRIB1 
demonstrated a potential mechanism in which binding of C/EBPα to TRIB1 facilitates the 
interaction of TRIB1 with the COP1 WD40 domain by releasing the C-terminal tail from its 
auto-inhibited state. Through this mechanism COP1 exerts its regulatory role on C/EBPα via 
promoting its ubiquitylation and subsequent degradation. The foundation of this mechanism 
is built on previous work that detailed the auto-inhibitory interaction of TRIB1 and the 
interaction between the C-terminal tail of TRIB1 and the COP1 WD40 domain (Murphy et 
al., 2015; Uljon et al., 2016). Understanding this mechanism is significant because, the 
dysregulation of C/EBPα is associated with AML, and could deliver insights into 
manipulating the mechanism for a therapeutic outcome. In relation to the studies focusing on 
oligomerisation in Chapter 3, there is not yet any definitive evidence that dimerisation of 
COP1 is required in its role of regulating C/EBPα. In future studies, it will be important to 
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Appendix A. PCR primers used in this study for cloning, mutagenesis, Colony PCR and 
DNA sequencing of COP1 constructs.   
Cloning primers 
COP1 110 Fw 5’-CAGGGACCCGGTAGCAGGAAGCGACCTCTCCTCG-3’ 
COP1 126 Fw 5’-CAGGGACCCGGTTCCTACGAGGACAAAAGCAACGACTTC-3’ 
COP1 351 Fw 5’-CAGGGACCCGGTAGCACGTTAGCATCAAGACGAAAACGAC-3’ 
COP1 376 Fw 5’-CAGGGACCCGGTATGTCTCGTATCTCAGATGACAGTCGAAC-3’ 
COP1 208 Rev 5’-CGAGGAGAAGCCCGGTTAGTCCAATTTGAACCTCTTTTCCTCAAATCTTTG-3’ 
COP1 308 Rev 5’-CGAGGAGAAGCCCGGTTACTCACTGACAGGAGAGTATAAGCCAC-3’ 
COP1 731 Rev 5’-CGAGGAGAAGCCCGGTTATACCAATTCTAGCACCTTAATTGTACCCTGAC-3’ 
Mutagenesis primers 
COP1 N186A Fw 5’-CCATCTGTATCCTGCTTTCTTGGTGAATGAACTCATTCTTAAACAG-3’ 
COP1 N186A Rev 5’-CATTCACCAAGAAAGCAGGATACAGATGGTCAATATTGTCCAC-3’ 
COP1 V189T Fw 5’-GTATCCTAATTTCTTGACGAATGAACTCATTCTTAAACAGAAG-3’ 
COP1 V189T Rev 5’-GAATGAGTTCATTCGTCAAGAAATTAGGATACAGATGGTC-3’ 
COP1 L192D Fw 5’- CTTGGTGAATGAAGACATTCTTAAACAGAAGCAAAGATTTG-3’ 
COP1 L192D Rev 5’- GTTTAAGAATGTCTTCATTCACCAAGAAATTAGGATACAG-3’ 
COP1 K127E Fw 5’- CAATAATAGATGTCCCGAGTGTAACTATGTTGTGGACAATATTG-3’ 
COP1 K127E Rev 5’- CAACATAGTTACACTCGGGACATCTATTATTGTCCTCCAAAC-3’ 
COP1 E191A Fw 5’- CTAATTTCTTGGTGAATGCACTCATTCTTAAACAGAAGCAAAGATTTG-3’ 
COP1 E191A Rev 5’- CTTCTGTTTAAGAATGAGTGCATTCACCAAGAAATTAGGATACAG-3’ 
Colony PCR/Sequencing primers 
T7 Fw 5’-TAATACGACTCACTATAGGG-3’ 
T7 Rev 5’-GCTAGTTATTGCTCAGCGG-3’ 
malE 5’-GGTCGTCAGACTGTCGATGAAGCC-3’ 
pUC/M13 Fw 5’-CCCAGTCACGACGTTGTAAAACG-3’ 




Appendix B. PCR protocols used during this study. 
Protocol ID Protocol process 
Q5 
1. 98 °C (30 seconds) 
2. 55 °C (30 seconds) 
3. 72°C (2 minutes) 
4. 98 °C (10 seconds) 
5. 72 °C (2 minutes) 
6. Repeat steps 4–5 (× 30) 
7. 72 °C (2 minutes) 
8. Hold 4 °C 
LIC 
1. 25 °C (30 minutes) 
2. 75 °C (20 minutes) 
3. Hold 4 °C  
QC 
1. 98 °C (1 minute) 
2. 98 °C (30 seconds) 
3. 55 °C (30 seconds) 
4. 72 °C (5 minutes) 
9. Repeat steps 2–4 (× 18) 
5. 72 °C (7 minutes) 
6. Hold 4 °C 
Colony 
1. 95 °C (2 minutes) 
2. 95 °C (30 seconds) 
3. 55 °C (30 seconds) 
4. 72 °C (4 minutes) 
5. Repeat steps 2–4 (× 33) 
6. 72 °C (6 minutes) 







Appendix C. Schematic of the all the COP1 constructs used in this study. Constructs were 
cloned from the ‘full-length’ COP1 construct (previously cloned by Dr Peter Mace). The 




Appendix D. Process of screening crystallisation conditions for the RING 2 construct. The 
SDS-PAGE analysis of the purification of a large-scale expression of RING 2 (A). The 
molecular mass (kDa) of the resolved marker bands are displayed on the left side. The 
soluble and insoluble fractions were collected from the cell lysate. The flow-through (FT) 
fraction was the portion of the cell lysate that did not bind the resin during IMAC, and the 
elution fractions resulted from IMAC. The sample loaded onto the Superdex 75 10/300 GL 
column (input). The SEC elution fraction labelled by their respective elution volumes 
corresponding to the elution profile (B), which shows the peak in absorbance at 280 nm 
detected by the inline UV detector of the ÄKTA Pure FPLC. Pooled fractions from the SEC 
purification indicated were concentrated and used for screening of crystallisation conditions. 
An example of the amorphous precipitant observed in a large proportion of the screened 








Appendix E. Ubiquitin chain building assay of COP1 RING and RING-COIL constructs. 
Assay reactions were quenched at time points 0, 5, 10, 20, and 60 minutes with sample 
buffer. Reactions were resolved via SDS-PAGE and stained with Coomassie Blue. The 
positions of the ubiquitin (Ub), E1 activating enzyme (E1), Ubc13, Mms2, RING, and RING-
COIL are labelled. The arrow represents the position of polyubiquitin species generated over 




Appendix F. Large-scale expression of WD40 2 construct via SF9 insect cell culture. 
Expression of the WD40 2 construct from 400 mL of SF9 cell culture was subsequently 
purified via IMAC and SEC. SEC was performed using a Superdex 75 10/300 GL column. 
The SEC chromatography elution profile (A) shows the peaks in absorbance at 280 nm 
detected by the inline UV detector of the ÄKTA Pure FPLC. Selected fractions from the SEC 
peaks were analysed via SDS-PAGE (B). The SDS-PAGE analysis included the protein 
sample post-IMAC that was loaded onto the SEC column (input) and the SEC elution 
fraction labelled by their respective elution volumes corresponding to the elution profile. The 
approximate molecular mass (kDa) of the bands are displayed on the left side. The bands 
corresponding to WD40 2 are boxed and labelled. Post-SEC, selected fractions were pooled 
and concentrated to generate a working stock of WD40 2 protein. The WD40 2 protein 
working stock was analysed via SDS-PAGE (C). The approximate molecular mass (kDa) of 
the bands are displayed on the left side and the band estimated to be WD40 2 is labelled.         
A 
C 
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